

UNIFORM GUIDANCE REPORTS AND SCHEDULES

Nationwide Children's Hospital, Inc. and Subsidiaries  
Years Ended December 31, 2022 and 2021  
With Reports of Independent Auditors

Ernst & Young LLP



Nationwide Children’s Hospital, Inc. and Subsidiaries

Uniform Guidance Reports and Schedules

Years Ended December 31, 2022 and 2021

**Contents**

Report of Independent Auditors .....	1
Consolidated Financial Statements	
Consolidated Balance Sheets .....	4
Consolidated Statements of Operations and Changes in Net Assets .....	6
Consolidated Statements of Cash Flows .....	8
Notes to Consolidated Financial Statements .....	9
Supplementary Information	
Schedule of Expenditures of Federal Awards .....	56
Notes to the Schedule of Expenditures of Federal Awards .....	78
Internal Control and Compliance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i> .....	79
Report of Independent Auditors on Compliance for the Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance .....	81
Schedule of Findings and Questioned Costs .....	85

## Report of Independent Auditors

The Board of Directors  
Nationwide Children's Hospital, Inc. and Subsidiaries

### Report on the Audit of the Financial Statements

#### *Opinion*

We have audited the consolidated financial statements of Nationwide Children's Hospital, Inc. and Subsidiaries (the Corporation), which comprise the consolidated balance sheets as of December 31, 2022 and 2021, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Corporation at December 31, 2022 and 2021, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### *Basis for Opinion*

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for one year after the date that the financial statements are issued.

### ***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### ***Supplementary Information***

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to April 26, 2023. The Schedule of Expenditures of Federal Awards, as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

### **Other Reporting Required by *Government Auditing Standards***

In accordance with *Government Auditing Standards*, we also have issued our report dated April 26, 2023, on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

*Ernst + Young LLP*

April 26, 2023, except for the schedule of expenditures of federal awards for which the date is September 29, 2023

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Balance Sheets

	<b>December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 432,579	\$ 307,740
Restricted cash	85,076	151,153
Short-term investments	50,776	—
Patient accounts receivable	368,076	367,423
Inventories	36,892	38,407
Pledges receivable <i>(Note 14)</i>	13,654	10,806
Premiums receivable	52,453	88,520
Other current assets	154,656	92,662
Total current assets	1,194,162	1,056,711
Assets limited as to use <i>(Note 5)</i> :		
Held by trustee	18,246	22,094
Board-designated:		
Capital improvement	71,084	78,167
Other	3,811,755	4,193,786
Donor restricted	445,541	414,893
Total assets limited as to use	4,346,626	4,708,940
Pledges receivable <i>(Note 14)</i>	25,450	12,768
Property and equipment, less allowance for depreciation <i>(Note 13)</i>	1,871,088	1,597,320
Other long-term assets	129,534	101,316
Total assets	<u>\$ 7,566,860</u>	<u>\$ 7,477,055</u>

	<b>December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
<b>Liabilities and net assets</b>		
Current liabilities:		
Accounts payable and accrued expenses	\$ 154,365	\$ 115,009
Compensation and related taxes	166,778	146,442
Current portion of long-term debt <i>(Note 8)</i>	83,718	81,107
Accrued claims expense	78,597	93,348
Other current liabilities	53,272	40,934
Total current liabilities	536,730	476,840
Long-term liabilities:		
Retirement benefits	10,720	13,901
Long-term debt <i>(Note 8)</i>	1,231,122	904,050
Professional liability	18,233	22,082
Other long-term liabilities	87,037	121,808
	1,347,112	1,061,841
Total liabilities	1,883,842	1,538,681
Net assets:		
Without donor restrictions:		
Nationwide Children's Hospital, Inc.	5,110,719	5,385,171
Noncontrolling interest <i>(Note 1)</i>	149,093	143,088
Total net assets, without donor restrictions	5,259,812	5,528,259
With donor restrictions <i>(Note 18)</i>	423,206	410,115
Total net assets	5,683,018	5,938,374
Total liabilities and net assets	\$ 7,566,860	\$ 7,477,055

*See accompanying notes.*

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Operations and Changes in Net Assets

	<b>Year Ended December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
<b>Unrestricted revenue, gains, and other support</b>		
Patient service revenue <i>(Note 4)</i>	\$ 1,743,537	\$ 1,578,564
Premium revenue	1,544,062	1,579,777
Other revenue	266,902	276,429
Net assets released from restrictions	41,493	35,157
Total unrestricted revenue, gains, and other support	<u>3,595,994</u>	<u>3,469,927</u>
<b>Expenses</b>		
Salaries and benefits	1,476,290	1,310,044
Claims expense	898,096	942,577
Supplies	374,752	340,650
Purchased services	243,505	163,999
Interest	26,482	31,640
Depreciation and amortization	114,568	109,778
Other	272,273	256,472
Total operating expenses	<u>3,405,966</u>	<u>3,155,160</u>
Operating income	<u>190,028</u>	<u>314,767</u>
Investment return – net <i>(Note 5)</i>	(522,006)	575,452
Other nonoperating gains – net <i>(Note 1)</i>	66,166	22,230
(Deficit) excess of revenue over expenses	<u>\$ (265,812)</u>	<u>\$ 912,449</u>

*Continued on next page*



Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Operations and Changes in Net Assets (continued)

	Year Ended December 31, 2022			Year Ended December 31, 2021		
	Attributable to	Attributable to		Attributable to	Attributable to	
	NCH	Noncontrolling Interests	Total	NCH	Noncontrolling Interests	Total
	(In Thousands)			(In Thousands)		
<b>Net assets without donor restrictions</b>						
(Deficit) excess of revenue over expenses	\$ (265,812)	\$ —	\$ (265,812)	\$ 912,449	\$ —	\$ 912,449
Change in pension obligation and assets	(1,335)	—	(1,335)	10,592	—	10,592
Net assets released from restrictions for the purchase of property and equipment	128	—	128	—	—	—
Issuance of noncontrolling interest	—	—	—	—	143,088	143,088
Transfers and other	(7,433)	6,005	(1,428)	(466)	—	(466)
(Decrease) increase in net assets without donor restrictions	(274,452)	6,005	(268,447)	922,575	143,088	1,065,663
<b>Net assets with donor restrictions</b>						
Contributions	72,467	—	72,467	39,212	—	39,212
Net assets released from restrictions for the purchase of property and equipment	(128)	—	(128)	—	—	—
Investment return, net	(25,952)	—	(25,952)	27,483	—	27,483
Net assets released from restrictions	(41,493)	—	(41,493)	(35,157)	—	(35,157)
Transfers and other	8,197	—	8,197	(3,992)	—	(3,992)
Increase in net assets with donor restrictions	13,091	—	13,091	27,546	—	27,546
(Decrease) increase in net assets	(261,361)	6,005	(255,356)	950,121	143,088	1,093,209
Net assets at beginning of year	5,795,286	143,088	5,938,374	4,845,165	—	4,845,165
Net assets at end of year	\$ 5,533,925	\$ 149,093	\$ 5,683,018	\$ 5,795,286	\$ 143,088	\$ 5,938,374

See accompanying notes.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Consolidated Statements of Cash Flows

	<b>Year Ended December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
<b>Operating activities</b>		
(Decrease) increase in net assets	\$ (255,356)	\$ 1,093,209
Adjustments to reconcile (decrease) increase in net assets to cash provided by (used in) operating activities:		
Net change in unrealized gains on investments	702,492	(386,803)
Change in fair value of interest rate swaps	(36,542)	(14,035)
Change in pension obligation and assets	1,335	(10,592)
Depreciation and amortization	115,414	107,417
Gain on bond refunding	(4,540)	—
Net changes in assets limited as to use	(340,178)	(416,248)
Restricted contributions and investment income	(80,083)	(50,322)
Change in noncontrolling interest	—	(143,088)
(Increase) decrease in:		
Short-term investments	(50,776)	—
Patient accounts receivable	(653)	(115,427)
Inventories	1,515	(14,064)
Premiums receivable	36,067	80,552
Other current assets	(61,994)	(15,639)
Pledges receivable	(15,530)	(206)
Other long-term assets	(28,218)	(19,898)
Increase (decrease) in:		
Accounts payable and accrued expenses	39,356	23,320
Compensation and related taxes	20,336	16,921
Other current liabilities	12,338	666
Accrued claims expense	(14,751)	(76,596)
Retirement benefits	(4,516)	(2,330)
Professional liability	(3,849)	(3,878)
Other long-term liabilities	1,771	10,379
Net cash provided by operating activities	<u>33,638</u>	<u>63,338</u>
<b>Investing activities</b>		
Purchase of property and equipment	(335,988)	(199,600)
Net cash used in investing activities	<u>(335,988)</u>	<u>(199,600)</u>
<b>Financing activities</b>		
Proceeds from issuance of long-term debt	431,855	75,000
Debt issuance costs	(3,897)	(6,641)
Repayment of long-term debt	(146,929)	(13,318)
Proceeds from issuance of noncontrolling interest	—	150,000
Noncontrolling interest issuance costs	—	(6,912)
Restricted contributions and investment income	80,083	50,322
Net cash provided by financing activities	<u>361,112</u>	<u>248,451</u>
Net increase in cash, cash equivalents and restricted cash	58,762	112,189
Cash, cash equivalents, and restricted cash at beginning of year	458,893	346,704
Cash, cash equivalents, and restricted cash at end of year	<u><u>\$ 517,655</u></u>	<u><u>\$ 458,893</u></u>

See accompanying notes.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

Years Ended December 31, 2022 and 2021

### 1. Organization and Significant Accounting Policies

Nationwide Children's Hospital, Inc. (Nationwide Children's) exclusively controls the activities of its subsidiaries in Central Ohio, including:

- **Nationwide Children's Hospital** (the Hospital) is a 772-bed not-for-profit tertiary care hospital, providing inpatient, outpatient, and emergency care services. Included within the bed count, the Hospital leases 145 neonatal intensive and special care nursery beds located at six other area hospitals. Subsidiaries of the Hospital include the following entities:
  - **Children's Radiological Institute** (CRI) is a not-for-profit professional practice plan owned by the Hospital, which provides radiological services at the Hospital.
  - **Nationwide Children's Hospital Homecare** (Homecare Services) is a not-for-profit home health company owned by the Hospital, which provides intermittent and private-duty nursing, skilled therapy, infusion therapy, durable medical equipment, hospice, and palliative care services.
  - **Pediatric Pathology Associates of Columbus** (PPAC) is a not-for-profit professional practice plan owned by the Hospital, which provides pathological services at the Hospital.
  - **Children's Surgical Associates** (CSA) is a not-for-profit professional practice plan owned by the Hospital, which provides surgical services at the Hospital.
  - **Pediatric Academic Association** (PAA) is a not-for-profit practice of which the Hospital owns 51%. The PAA is a group of over 500 medical, pediatric sub-specialists, which provides such services at the Hospital. The remaining 49% ownership interest held by The Ohio State University Clinical Practice Plan was transferred to the faculty members of the Department of Pediatrics of The Ohio State University College of Medicine. The non-controlling interest was \$(1,021,000) and \$5,000 as of December 31, 2022 and 2021, respectively.
  - **Children's Anesthesia Associates, Inc.** (CAA) is a not-for-profit professional practice plan which provides anesthesiology services at the Hospital.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 1. Organization and Significant Accounting Policies (continued)

- **Nationwide Children's Hospital Foundation** (Foundation) is a not-for-profit charitable foundation.
- **The Research Institute at Nationwide Children's Hospital** (Research Institute) is a not-for-profit pediatric medical research institute.
- **Center for Child and Family Advocacy at Nationwide Children's Hospital** (CCFA) is a not-for-profit organization that provides advocacy, education, counseling and other programmatic services to children and families suffering from child abuse and neglect. CCFA also is known by its operating name – The Center for Safety and Family Healing.
- **Children's Hospital and Physicians Healthcare Network** (d/b/a Partners for Kids) is a joint venture between the Hospital and community physicians. Partners for Kids is a not-for-profit formed to contract with insurers offering Medicaid or commercial managed care products for the provision of medical services. As a result of the Hospital's affiliation with certain physician groups, the Hospital has effective control of the Partners for Kids board and an economic interest in Partners for Kids.
- **Andelyn Biosciences, Inc. (Andelyn)** is a for-profit Phase 3 compliant Goods Manufacturing Practices (GMP) clinical manufacturing facility, producing materials for Phase 1, 2, and 3 gene therapy clinical studies for biotechnology and pharmaceutical industries. Andelyn is majority owned by Nationwide Children's and was formerly known as Pediatric Clinical Trials International, Inc. (PCTI). In March 2021, Nationwide Children's sold a minority equity ownership interest in Andelyn for \$150,000,000. In addition, Andelyn entered into a \$75,000,000 term loan with a private investor. Proceeds from these transactions will support construction of a \$200,000,000 manufacturing facility, operating cash flow requirements, and transaction costs. There was no change in control as a result of the transaction, and no gain recorded as a result. The agreement with the minority shareholder includes a purchase option, which provides the minority shareholder with the right to purchase shares of Andelyn from Nationwide Children's at fair value at any time following March 2025. Due to Nationwide Children's controlling equity interest, Andelyn will continue to be consolidated for financial reporting purposes. The non-controlling interest was \$150,114,000 and \$143,088,000 as of December 31, 2022 and 2021, respectively. The governing documents of Andelyn indicate that preferred shares are to be paid a dividend equal to 5% of their original issue price each year, on April 1, for the first four years they are outstanding. The increase in non-controlling interest was caused by the payment of dividends of \$7,026,000 during the year-ended December 31, 2022.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 1. Organization and Significant Accounting Policies (continued)

#### Basis of Presentation

The consolidated financial statements include the accounts of Nationwide Children's Hospital, Inc. and its subsidiaries, collectively referred to as Nationwide Children's or the Corporation. Significant inter organization accounts and transactions have been eliminated in consolidation.

#### Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

#### Cash, Cash Equivalents, and Restricted Cash

Nationwide Children's defines cash as currency on hand and demand deposits with financial institutions. Cash equivalents are defined as short-term, highly liquid investments with remaining maturities of three months or less at the time of acquisition, excluding those held in assets limited as to use. The components of cash, cash equivalents, and restricted cash for the years ended December 31 are as follows:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Cash and cash equivalents	\$ 432,579	\$ 257,663
Restricted cash	85,076	151,153
Total	<u>\$ 517,655</u>	<u>\$ 458,893</u>

#### Investments

Investments in equity securities and mutual funds with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheets. Investment return (including interest and dividends, realized gains and losses on the sale of investments, and changes in unrealized gains and losses on investments) is included in the (deficit) excess of revenue over expenses, unless the income or loss is restricted by the donor or law.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **1. Organization and Significant Accounting Policies (continued)**

##### **(Deficit) Excess of Revenue Over Expenses**

The consolidated statements of operations and changes in net assets include (deficit) excess of revenue over expenses as the performance indicator. Changes in net assets, which are excluded from (deficit) excess of revenue over expenses, consistent with industry practice, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction, were to be used for the purposes of acquiring such assets), transfers and the change in pension obligations and assets.

##### **Patient Accounts Receivable and Patient Service Revenue**

Patient service revenue and patient accounts receivable are reported at the amount that reflects the consideration to which Nationwide Children's expects to be entitled in exchange for providing patient care.

##### **Premium Revenue and Claims Expense**

###### *Premium Revenue*

Premium revenue represents revenue derived under capitated arrangements between Partners for Kids and third parties, whereby Partners for Kids receives a per member per month (PMPM) amount for enrolled members. In return for these premiums, Partners for Kids has a performance obligation to provide essentially all health care services to enrolled participants for the duration of the contract. Premium revenue is recognized as Partners for Kids satisfies its performance obligations over time in the month in which the members are entitled to receive health care services. Under these capitated agreements, Partners for Kids assumes the economic risk of the members' health care services and related administrative costs. Partners for Kids may also receive retroactive adjustments to the health care premiums received based on the quality scores. The factors considered in this may change from year to year, but during the Public Health Emergency related to the COVID-19 Pandemic, the factors were based on vaccination compliance in 2021 and the first half of 2022. In addition, the number of the members for whom Partners for Kids receives health care premiums may be retroactively adjusted due to enrollment changes not yet processed or reported. Partners for Kids generally estimates these retroactive adjustments using an expected value methodology, and amounts are only included to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 1. Organization and Significant Accounting Policies (continued)

As the performance obligation recognized over time relates to contracts with a duration of one year or less, Partners for Kids has elected the practical expedient in Accounting Standards Codification (ASC) 606, *Revenue From Contracts With Customers*, which provides relief from the requirement to disclose the transaction price for remaining performance obligations at the end of each reporting period and the requirement to disclose when the company expects to recognize the related revenue.

During 2020, Partners for Kids expanded its operations into several counties in Ohio which contributed to growth in premium revenues, claims expenses, and related receivables and payables. In 2020, due to a delay and limitation in the ability of the managed care plan to automate data for a portion of the year, no funds were paid or received during 2020, and an estimate was recorded for the premium revenue and related receivable, as well as claims expense and related claims payable for the regions impacted. During 2021, a final settlement was determined and resulted in \$17 million favorable development recorded as a reduction to claims expense, which represented a change in estimate. During 2022, the Ohio Department of Medicaid (ODM) launched part of its "Next Generation of Ohio Medicaid Managed Care" program which emphasizes strong cross-agency coordination and partnerships among managed care plans, vendors, sister state agencies, and ODM to support specialization in addressing critical needs. OhioRISE (Resilience through Integrated Systems and Excellence), a specialized managed care program for youth with complex behavioral health and multisystem needs, became effective July 1, 2022 and resulted in the removal of the risk associated with certain behavioral health services for children that qualify for OhioRISE. The impact of OhioRISE in the current year was approximately a 5% reduction in Partners for Kid's PMPM rate. Additionally, the Single Pharmacy Benefit Manager (SPBM) was implemented effective October 1, 2022 and removed the risk associated with retail pharmacy costs and certain drug costs contained within medical services. The impact of SPBM in the current year was approximately a 16% decrease in Partners for Kid's PMPM rate.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 1. Organization and Significant Accounting Policies (continued)

Partners for Kids generates premium revenue through capitated contracts solely with Ohio Medicaid payors comprised of Medicaid programs: Covered Families and Children (CFC), Aged, Blind, and Disabled (ABD), and Adoption and Foster Kids (AFK). For the years ended December 31, premium revenue is as follows:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
CFC	<b>\$ 1,261,702</b>	\$ 1,273,463
ABD	<b>207,297</b>	220,711
AFK	<b>75,063</b>	85,603
Total, December 31	<b><u>\$ 1,544,062</u></b>	<b><u>\$ 1,579,777</u></b>

#### *Claims Expense and Accrued Claims Expense*

Claims expense represents the cost of third-party health care services provided to members who are attributed to Partners for Kids for benefits covered within the capitated agreement. Claims expense does not include cost of services provided by Nationwide Children's. Claims expense is recognized in the period in which services are provided. This includes both claim payments processed in the period and also an estimate of the obligations for claims incurred but not reported. On an ongoing basis, Partners for Kids develops the estimated medical claims payable. This process includes utilizing actuarial models when a sufficient amount of medical claims history is available from the third-party health care service providers. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, medical care utilization and other medical cost trends, membership volume and demographics. Partners for Kids reexamines previously recorded medical claims payable estimates based on actual claims submissions and other changes in facts and circumstances. As medical claims expense recorded in prior periods becomes more exact, Partners for Kids adjusts the amount of the estimate, and includes the change in medical claims expense in the period in which the change is identified. In each reporting period, total medical claims expense includes a change from the effects of more completely developed medical claims expense payable estimates associated with previously reported periods. While the Corporation believes its estimated incurred but not reported claims is adequate to cover future claims payments required, such estimates are based on its claims experience to date and various assumptions. Therefore, the actual liability could differ materially from the amount recorded.



# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 1. Organization and Significant Accounting Policies (continued)

Under the risk agreement, Partners for Kids is responsible for substantially all of the costs of all medical services provided to each member. Partners for Kids does not anticipate that revenues resulting from the risk arrangement will be insufficient to cover associated claims expenses from the period. If deemed necessary, Partners for Kids would recognize a premium deficiency liability. There is no premium deficiency liability recorded at December 31, 2022 and 2021.

Partners for Kids maintains stop-loss insurance coverage to limit exposure for certain catastrophic claims. The policy limit is \$2,000,000 per year per claim.

For the years ended December 31, activity in the accrued claims expense is as follows:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Balance, January 1	\$ 93,348	\$ 169,944
Incurred related to:		
Current period	813,880	851,799
Prior periods	(11,129)	(24,764)
Paid related to:		
Current period	(735,663)	(765,147)
Prior periods	(81,839)	(138,484)
Balance, December 31	<u>\$ 78,597</u>	<u>\$ 93,348</u>

### Inventories

Inventories, consisting of drugs, medical and surgical supplies, are valued at the lower of cost, determined on a first-in, first-out basis, or market.

### Property and Equipment

Property and equipment are stated at cost or at estimated fair value if acquired by gift. Depreciation of property and equipment is provided on the straight-line method at rates based on the estimated useful lives of the assets.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 1. Organization and Significant Accounting Policies (continued)

##### Bond Issuance Costs

Nationwide Children's records certain costs associated with the issuance of its bonds and reports these costs as a reduction in the related debt. The costs are amortized over the life of the bonds using a method that approximates the effective interest method.

##### Derivatives

Nationwide Children's uses interest rate swaps as part of its overall debt management policy. Nationwide Children's accounts for interest rate swaps in accordance with ASC 815, *Derivatives and Hedging*, which requires that all derivatives be carried at fair value in the consolidated balance sheets. The related changes in fair value are reported in the consolidated statements of operations and changes in net assets as a component of (deficit) excess of revenue over expenses.

##### Fair Value

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value assessments are made at a specific point in time based on relevant market information about the financial instrument. See Note 6 for a description of the fair value hierarchy.

##### Community Benefits and Charity Care

Nationwide Children's provides programs and services to address the needs of those in the community with limited financial resources, generally at no or low cost to those being served. Additional services are provided to beneficiaries of governmental programs (principally those relating to the Medicare and Medicaid programs) at substantial discounts from established rates and are considered part of Nationwide Children's benefit to the community.

Assistance also is provided as needed to patients and their families for the submission of forms for insurance, financial counseling, and application to the Medicare and Medicaid programs for health service coverage. In addition, interpretive services are provided to those families who either cannot or have difficulty speaking English. The costs of providing these programs and services are included in expenses.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 1. Organization and Significant Accounting Policies (continued)

Consistent with Nationwide Children's mission, care is provided to patients regardless of their ability to pay. Patients who meet certain criteria for charity care are provided care without charge or at amounts less than established rates. Because collection of amounts determined to qualify as charity care is not pursued, such amounts are not reported as patient service revenue. Records are maintained to identify and monitor the level of charity care provided, including the amount of charges foregone for services and supplies furnished. The amount of charges foregone for services and supplies furnished under Nationwide Children's charity care policies for the years ended December 31 are as follows:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Charges foregone, based on established rates	<b>\$ 59,097</b>	<b>\$ 45,726</b>
Management's estimate of costs incurred to provide charity care	<b>\$ 27,167</b>	<b>\$ 22,040</b>
Equivalent percentage of cost of charity care services to patient service revenue, based on established rates	<b>45.97%</b>	<b>48.20%</b>

Estimates of costs incurred to provide charity care are based upon historical amounts derived from Medicaid cost reports.

### Operating and Nonoperating Activities

Nationwide Children's principal activity is the provision of diversified health care services to the community. As such, activities related to the ongoing operations of Nationwide Children's are classified as revenue. Other revenue includes those generated from patient care related support services, research, certain donated revenue, royalty revenue from licensing agreements, and sundry revenue related to the operation of Nationwide Children's. Gains and losses not directly related to the ongoing operations of Nationwide Children's or that occur infrequently are reported as nonoperating gains and losses. Included in nonoperating gains and losses are unrestricted contributions, changes in fair value of interest rate swaps, gain on bond refunding, revenue and costs associated with technology commercialization investments, and gains on the sale of property and equipment.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 1. Organization and Significant Accounting Policies (continued)

The following table sets forth other non-operating gains – net for the years ended December 31:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Unrestricted contributions	\$ 15,475	\$ 7,086
Change in fair value of interest rate swaps	36,542	14,035
Technology investments	42	56
Gain on bond refunding	4,540	—
Other	9,567	1,053
Other nonoperating gains – net	<u>\$ 66,166</u>	<u>\$ 22,230</u>

### Federal Income Taxes

Nationwide Children's is incorporated under the laws of the State of Ohio. Nationwide Children's and its subsidiaries, except Andelyn and NCH Realty, Inc., are tax-exempt organizations as defined under Section 501(c)(3) of the Internal Revenue Code. Income taxes on the for-profit subsidiaries, Andelyn and NCH Realty, Inc., are not significant.

Nationwide Children's records accruals for uncertain tax positions under ASC 740, *Income Taxes*. Nationwide Children's had no significant uncertain tax positions as of December 31, 2022 and 2021.

### COVID-19 Pandemic

On March 11, 2020, the World Health Organization declared the outbreak of Coronavirus Disease 2019 (COVID-19), a disease caused by a novel strain of coronavirus, a global pandemic. Federal and state governments enacted legislation and administrative actions to assist health care facilities in providing care to patients during the pandemic. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted. Among other provisions, the CARES Act authorized relief funding to health care providers through the Public Health and Social Services Emergency Fund (Provider Relief Fund). The U.S. Department of Health and Human Services (HHS) is planning for the federal public health emergency declared for COVID-19 to expire on May 11, 2023.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **1. Organization and Significant Accounting Policies (continued)**

##### *CARES Act Provider Relief and Other Funding*

Distributions from the Provider Relief Fund are intended to reimburse health care providers for lost revenue and increased expenses related to the pandemic and are not subject to repayment; however, Nationwide Children's must attest to certain terms and conditions set forth by the legislation including, among other things, that distributions received were used for expenses and lost revenue resulting from COVID-19. Distributions provided by the CARES Act Provider Relief Fund are recognized as revenue once the applicable terms and conditions required to retain the distributions are met. Management performs ongoing analyses of the impact of the pandemic on Nationwide Children's operations and considers the compliance and reporting requirements set forth by the CARES Act, including subsequent issuance of all frequently asked questions and interpretive guidance issued by the HHS, to determine the amount of government funds to recognize. The Provider Relief Fund Payment Terms and Conditions distributed by the HHS directs recipients to use distributed funds to prevent, prepare for, and respond to the COVID-19 pandemic and reimburses recipients only for health care expenses and lost revenues attributable to the pandemic. Guidance on the recognition and reporting of government stimulus funds continues to evolve through the issuance of Post-Payment Notices of Reporting Requirements, each of which supplements and supersedes previously issued notices. During the year ended December 31, 2022, Nationwide Children's has received approximately \$35,668,000 of Provider Relief Fund payments that was recognized as other revenue in the accompanying consolidated statement of operations and changes in net assets. Issuance of new guidance and/or amended interpretations of existing guidance may result in changes to management's estimate of government stimulus revenue and, in certain cases, may result in derecognition of amounts previously recognized. No Provider Relief Fund payments were received or recognized during the year ended December 31, 2021.

##### **Reclassifications**

Certain amounts in the 2021 consolidated balance sheet have been reclassified to conform to the 2022 presentation. Such reclassifications had no effect on previously reported total assets, total liabilities, or total net assets.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 2. Newly Adopted Accounting Guidance

In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, *Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment*. This guidance eliminates Step 2 from the goodwill impairment test. Instead, an entity will test goodwill by comparing the fair value of a reporting unit with the carrying amount. This ASU is effective in the reporting period beginning January 1, 2022. Nationwide Children's adopted this guidance on January 1, 2022 and there were no material impacts to the consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes*. This guidance provides clarification on income taxes under ASC 740 by removing certain exceptions and improving consistent application of existing guidance. This ASU is effective in the reporting period beginning January 1, 2022. Nationwide Children's adopted this guidance on January 1, 2022 and there were no material impacts to the consolidated financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This guidance changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about contributed nonfinancial assets. This ASU is effective in the annual reporting period beginning January 1, 2022. Nationwide Children's adopted this guidance on January 1, 2022 and there were no material impacts to the consolidated financial statements.

#### 3. Third-Party Settlements

Estimated third-party settlements for various programs (Bureau of Children with Medical Handicaps, Medicare and Medicaid) reflect differences between interim reimbursement and reimbursement as determined by reports filed after the end of each year. In addition, such third-party settlements reflect, if applicable, any differences found to be owed to or by the Hospital after government agencies have audited these reports. The Hospital has received interim payments under Title V (Bureau of Children with Medical Handicaps) and Title XIX (Medicaid) programs but has not yet received final settlement for the years 2013 through 2022. Final settlement of amounts is subject to audit and verification by the appropriate governmental agency. The amounts reported in the consolidated financial statements represent the estimated settlements outstanding, which the Hospital's management believes will approximate final settlements.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **3. Third-Party Settlements (continued)**

Revenue from the Medicaid program accounted for 21% and 20% of the Hospital's patient service revenue for the years ended December 31, 2022 and 2021, respectively. Laws and regulations governing the Medicaid program are complex and subject to interpretation. The Hospital believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicaid program. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

#### **4. Patient Service Revenue**

Nationwide Children's provides health care services through inpatient, outpatient, and ambulatory care facilities. Patient service revenue is reported at the amount that reflects the consideration to which Nationwide Children's expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, Nationwide Children's bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by Nationwide Children's. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Nationwide Children's believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation, based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the hospital receiving inpatient acute care services. Nationwide Children's measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided, and Nationwide Children's does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, Nationwide Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 4. Patient Service Revenue (continued)

allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Nationwide Children's uses a portfolio approach to account for categories of patient contracts as a collective group, rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and outpatient revenue. Based on the historical collection trends and other analysis, Nationwide Children's believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Nationwide Children's determines the transaction price based on standard charges for goods and services provided, reduced by explicit price concessions provided to third-party payors, discounts provided to uninsured patients in accordance with Nationwide Children's policy, and/or implicit price concessions provided to uninsured patients. Nationwide Children's determines its estimates of explicit price concessions based on contractual agreements, its discount policy, and historical experience. Nationwide Children's determines its estimate of implicit price concessions based on its historical collection experience with each class of patients.

Revenue from third-party payors is subject to retroactive adjustments due to audits, reviews, changes in program administration and rules, and outcome of litigation. These settlements are estimated based on the agreement with the payor and correspondence, which includes an assessment to ensure it is probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved.

Agreements with third-party payors typically provide for payments at amounts less than established charges. The following is a summary of the payment arrangements with major third-party payors:

**Commercial:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.



## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 4. Patient Service Revenue (continued)

**Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.

The Ohio Department of Medicaid administers a federally sponsored program, which provides additional reimbursement to hospitals that serve a disproportionate share of indigent patients (Care Assurance Program). The current program allocation formula generally is based on individual hospitals' components of indigent care in relation to statewide totals. Future funding of the Care Assurance Program is contingent on annual governmental approval, and the program's long-term existence is uncertain.

For the years ended December 31, 2022 and 2021, revenue recognized related to this program was recorded within patient service revenue in the consolidated statements of operations and changes in net assets, totaling \$79,018,000 and \$45,002,000, with offsetting HCAP assessments of \$6,252,000 and \$5,731,000, respectively. Nationwide Children's has recorded a liability of \$57,394,000 in other long-term liabilities in the consolidated balance sheets as of December 31, 2022 and 2021, related to this program. Of this amount, \$30,676,000 relates to 2015 and \$26,718,000 relates to 2014, based on information provided by the Ohio Department of Medicaid during 2015.

**Self Pay:** Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. Nationwide Children's also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. Nationwide Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. For the years ended December 31, 2022 and 2021, the changes to the estimates of implicit price concessions for performance obligations satisfied in prior years were not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2022 and 2021 was \$441,000 and \$352,000, respectively.

**Other:** Payment agreements with certain governmental insurance carriers, government agencies, and non-government organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 4. Patient Service Revenue (continued)

Patient service revenue by major payor source for the years ended December 31 is as follows:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Commercial	<b>\$ 1,321,597</b>	\$ 1,216,948
Medicaid	<b>374,160</b>	308,760
Self-pay	<b>2,703</b>	14,172
Other	<b>45,077</b>	38,684
	<b><u>\$ 1,743,537</u></b>	<b><u>\$ 1,578,564</u></b>

Nationwide Children's has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component, due to Nationwide Children's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, Nationwide Children's does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 5. Assets Limited as to Use

The composition of assets limited as to use at December 31 is set forth in the following table:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Trustee funds:		
Cash equivalents	\$ 2,338	\$ 2,703
Fixed income:		
Mutual funds	7,743	9,574
Equities – mutual funds:		
Domestic large-cap indexed	3,477	4,341
Domestic mid-cap indexed	583	686
Domestic small-cap	867	1,169
International	2,384	2,634
Commodities fund	854	987
	<b>18,246</b>	<b>22,094</b>
Board-designated capital improvement:		
Cash equivalents	972	622
Fixed income:		
U.S Treasury bonds	2,207	2,596
U.S. Treasury notes	11,964	14,421
U.S. Government agencies	6,809	5,430
Corporate obligations	13,365	14,496
Foreign obligations	934	589
Mutual funds	6,412	6,624
Equities – mutual funds:		
Domestic large-cap indexed	11,058	14,169
Domestic mid-cap indexed	1,829	2,251
Domestic small-cap	1,319	1,780
International	6,631	7,541
Equity securities:		
Domestic small-cap	1,720	1,896
Commodities fund	4,253	3,688
Private equity	1,611	2,064
	<b>71,084</b>	<b>78,167</b>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

**5. Assets Limited as to Use (continued)**

	2022	2021
Board-designated other:		
Cash equivalents	\$ 191,637	\$ 201,484
Fixed income:		
U.S. Treasury bonds	41,295	48,732
U.S. Treasury notes	87,477	90,209
U.S. Government agencies	176,605	169,771
Corporate obligations	145,938	154,807
Foreign obligations	36,842	34,007
Mutual funds	315,051	353,495
Equities – mutual funds:		
Domestic large-cap indexed	1,172,278	1,405,165
Domestic mid-cap indexed	195,890	225,839
Domestic small-cap	145,635	166,536
International	653,415	730,307
Equity securities:		
Domestic small-cap	167,099	174,429
Commodities fund	200,935	177,321
Private equity and private credit	281,658	261,684
	<u>3,811,755</u>	<u>4,193,786</u>
Donor restricted:		
Cash equivalents	30,371	49,212
Fixed income:		
U.S. Treasury bonds	6,188	6,358
U.S. Treasury notes	21,833	20,964
U.S. Government agencies	23,295	18,674
Corporate obligations	28,513	26,162
Foreign obligations	4,290	3,276
Mutual funds	31,026	25,918
Equities – mutual funds:		
Domestic large-cap indexed	113,634	117,094
Domestic mid-cap indexed	18,572	18,482
Domestic small-cap	13,949	13,994
International	79,348	60,226
Equity securities:		
Domestic small-cap	15,835	14,099
Commodities fund	28,036	19,426
Private equity and private credit	29,818	20,100
Other	833	908
	<u>445,541</u>	<u>414,893</u>
Total assets limited as to use	<u>\$ 4,346,626</u>	<u>\$ 4,708,940</u>

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 5. Assets Limited as to Use (continued)

Nationwide Children's has committed capital yet to be called of approximately \$163,000,000 at December 31, 2022, to private equity and private credit funds over the next four to six years.

As of December 31, 2022 and 2021, assets limited as to use included an investment in a mutual fund equaling approximately 30% and 33%, respectively, of the consolidated investment balance. This passively managed fund is indexed to the S&P 500; therefore, management believes no concentration of credit risk exists with regard to this investment.

The composition of the investment return on board designated and funds held by trustee recognized in the consolidated statements of operations and changes in net assets is as follows for the years ended December 31:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Investment return – net:		
Dividend and interest income	\$ 116,580	\$ 85,284
Realized gains on the sale of investments, net	30,337	119,738
Unrealized (losses) gains on investments, net	(668,923)	370,430
	<u>\$ (522,006)</u>	<u>\$ 575,452</u>

The composition of the investment return on donor restricted assets limited as to use recognized in the consolidated statements of operations and changes in net assets is as follows for the years ended December 31:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Investment return – net:		
Dividend and interest income	\$ 6,351	\$ 4,665
Realized gains on the sale of investments, net	1,266	6,445
Unrealized (losses) gains on investments, net	(33,569)	16,373
	<u>\$ (25,952)</u>	<u>\$ 27,483</u>

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 6. Fair Value Measurements

Below is the fair value hierarchy that categorizes into three levels the inputs to valuation techniques that are used to measure fair value:

- Level 1 includes observable inputs that reflect quoted prices for identical assets or liabilities in active markets at the measurement date.
- Level 2 includes observable inputs for assets or liabilities other than quoted prices included in Level 1, and valuation techniques that use prices for similar assets and liabilities.
- Level 3 includes unobservable inputs that reflect the reporting entity's estimates of the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).

Management's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

Cash and cash equivalents principally are invested in money market funds. The money market funds are valued at their net asset value. Net asset value is equal to the fair value of each money market fund's investments and other assets, less liabilities, divided by the number of fund shares.

The money market funds are comprised of highly liquid investments with maturities of three months or less at date of acquisition and are classified as Level 1 instruments. Equity securities and mutual funds are valued at the closing price on the exchange where the security principally is traded, a market-based valuation technique. The instruments are classified as Level 1, because quoted prices in active markets are available. Nationwide Children's does not adjust quoted prices for such instruments.

U.S. Treasury bonds, U.S. Treasury notes, U.S. Government agencies, and corporate obligations are valued based upon a compilation of primarily observable market information or quoted prices that are not active. Foreign obligations are valued using vendor-evaluated prices. Because the evaluated prices for these fixed-income securities are based upon observable inputs, such as available trade information, spreads, bids and offers, broker feeds and reported trades, adjustments for corporate actions, and benchmark yields, instruments in these categories are classified as Level 2 securities. For interest rate swap liabilities, the Corporation uses a discounted cash flow analysis, incorporating interest rates and London Interbank Offered Rate (LIBOR) curves

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 6. Fair Value Measurements (continued)

when assessing fair value, an income-based valuation technique. Such instruments generally are classified as Level 2 securities. There are certain commodities funds, private equity and private credit investments that are accounted for using the equity method of accounting. These investments (certain commodities funds of \$117,700,000 and \$94,083,000 at December 31, 2022 and 2021, respectively, and private equity and private credit totaling \$313,087,000 and \$283,848,000 at December 31, 2022 and 2021, respectively) are not required to be marked to fair value on a recurring basis and, therefore, are not included in the accompanying tables. The carrying values of these investments are based on valuations provided by the administrators of the specific financial instruments. The underlying investments in these financial instruments may include marketable debt and equity securities, commodities, foreign currencies, derivatives, and private equity investments. The underlying investments are subject to various risks, including market, credit, liquidity, and foreign exchange risk. Nationwide Children's believes the carrying amount of these financial instruments in the consolidated balance sheets is a reasonable estimate of its ownership interest in the private equities. Because some of these financial instruments are not readily marketable, the estimated carrying value is subject to uncertainty and, therefore, may differ from the value that would have been used had a public market for such financial instruments existed. Nationwide Children's risk related to private equities is limited to its carrying value plus amounts committed to private equity as disclosed in Note 5. The private equity investments also have certain liquidity restrictions which generally range for the life of the fund. Once capital is contributed to a private equity fund, distribution timing is subject to the manager during the life of the fund.

The carrying amounts of the variable rate, long-term debt, as detailed in Note 8, approximate their fair values. The fair value of the fixed-rate, long-term debt is estimated using a discounted cash flow analysis, based on current incremental borrowing rates for similar types of borrowing arrangements. The fair value of the fixed rate, long-term debt at December 31, 2022 and 2021 is approximately \$771,082,000 (carrying value \$881,790,000) and \$730,975,000 (carrying value \$645,585,000), respectively. Nationwide Children's debt obligations are classified consistent with Level 2 of the fair value hierarchy. The fair value of short term investments are classified as Level 1 of the fair value hierarchy.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 6. Fair Value Measurements (continued)

The following tables set forth Nationwide Children's assets and liabilities measured at fair value on a recurring basis as of December 31, aggregated by the level in the fair valued hierarchy within which those measurements are measured:

	2022			Total Fair
	Level 1	Level 2	Level 3	Value
	<i>(In Thousands)</i>			
<b>Assets</b>				
Cash and cash equivalents	\$ 225,318	\$ —	\$ —	\$ 225,318
Fixed income:				
U.S. Treasury bonds	—	49,690	—	49,690
U.S. Treasury notes	—	121,274	—	121,274
U.S. Government agencies	—	206,709	—	206,709
Corporate obligations	—	187,816	—	187,816
Foreign obligations	—	42,066	—	42,066
Mutual funds	357,741	2,491	—	360,232
Equities – mutual funds:				
Domestic large-cap indexed	1,300,447	—	—	1,300,447
Domestic mid-cap indexed	216,874	—	—	216,874
Domestic small-cap	161,770	—	—	161,770
International	689,650	52,128	—	741,778
Equities – securities:				
Domestic small cap	184,654	—	—	184,654
Commodities	115,218	—	—	115,218
Other	—	833	—	833
Total assets	<u>\$ 3,251,672</u>	<u>\$ 663,007</u>	<u>\$ —</u>	<u>\$ 3,914,679</u>
<b>Liabilities</b>				
Interest rate swaps (asset)	\$ —	\$ (3,819)	\$ —	\$ (3,819)
Total liabilities	<u>\$ —</u>	<u>\$ (3,819)</u>	<u>\$ —</u>	<u>\$ (3,819)</u>



Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

**6. Fair Value Measurements (continued)**

	<b>2021</b>			<b>Total Fair</b>
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Value</b>
	<i>(In Thousands)</i>			
<b>Assets</b>				
Cash and cash equivalents	\$ 254,021	\$ —	\$ —	\$ 254,021
Fixed income:				
U.S. Treasury bonds	—	57,686	—	57,686
U.S. Treasury notes	—	125,594	—	125,594
U.S. Government agencies	—	193,875	—	193,875
Corporate obligations	—	195,465	—	195,465
Foreign obligations	—	37,872	—	37,872
Mutual funds	392,971	2,640	—	395,611
Equities – mutual funds:				
Domestic large-cap indexed	1,540,769	—	—	1,540,769
Domestic mid-cap indexed	247,258	—	—	247,258
Domestic small-cap	183,479	—	—	183,479
International	800,708	—	—	800,708
Equities – securities:				
Domestic small cap	190,424	—	—	190,424
Commodities	105,850	—	—	105,850
Other	—	908	—	908
Total assets	<u>\$ 3,715,480</u>	<u>\$ 614,040</u>	<u>\$ —</u>	<u>\$ 4,329,520</u>
<b>Liabilities</b>				
Interest rate swaps	\$ —	\$ 32,723	\$ —	\$ 32,723
Total liabilities	<u>\$ —</u>	<u>\$ 32,723</u>	<u>\$ —</u>	<u>\$ 32,723</u>

The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are reasonable estimates of fair value due to the short-term nature of these financial instruments.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **7. Professional Liability Self-Insurance and Litigation**

Nationwide Children's is subject to threatened legal actions, which arise in the normal course of its operating activities. Nationwide Children's risk management program regularly monitors its operations for potential claims. Various claimants have asserted professional and patient general liability claims for incidents that may give rise to litigation against Nationwide Children's. The claims are in various stages of evaluation and some ultimately may be brought to trial. There are also known incidents that have occurred through the end of the period ended December 31, 2022, which may result in the assertion of additional claims, and there may be other claims related to unreported incidents arising from services provided to patients.

Nationwide Children's has employed independent actuaries to estimate the ultimate cost, if any, of the settlement of such claims. Accrued professional liability losses have been discounted at an annual rate of 1.45% at December 31, 2022 and 2021, and, in management's opinion, provide adequate reserves for loss contingencies. As the actuarially determined accrual for professional and general liability is an estimate, the possibility exists that the estimate could be revised by a material amount in the near term.

To fund its self-insurance liability, Nationwide Children's maintains a trustee-held investment fund. Under the trust agreement, the trust assets can only be used for payment of professional and patient general liability losses, related expenses, and the cost of administering the trust.

On June 6, 2014 the United States Department of Treasury (DOT) concluded that the Hospital had violated certain provisions of the Code of Federal Regulations, which govern the use of the State and Local Government Series (SLGS) securities over a period from 2008 through 2012 in connection with advanced refunding of tax-exempt debt. As a consequence, the DOT suspended the Hospital from participating in the SLGS program for five years, with the possibility of a waiver with respect to certain purchases of SLGS securities. The Hospital disagreed with the DOT's decision, but elected not to contest the conclusion or suspension in court. On May 13, 2016, the United States Department of Justice (DOJ) informed the Hospital of its intention to investigate the Hospital's use of SLGS securities under the False Claims Act. The Hospital previously had discussions with the DOJ but has not had any discussions with the government since October 2018. At this time, the Hospital cannot predict the outcome of the DOJ investigation, including the potential materiality of any monetary consequences, and the Hospital cannot presently estimate the amount of contingent liability, if any, and therefore no liability amount has been recognized in the consolidated financial statements. The DOJ's investigation and related future claims, if any, if decided adversely to the interests of the Hospital, could be material to the Nationwide Children's.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 8. Long-Term Debt

Long-term debt consisted of the following at December 31:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Hospital Improvement Revenue Bonds, Series 2022A	\$ 300,000	\$ —
Hospital Improvement Revenue Bonds, Series 2022B	63,900	—
Hospital Improvement Revenue Bonds, Series 2022C	67,955	—
Hospital Improvement Revenue Bonds, Series 2020	148,925	148,925
Hospital Improvement Revenue and Improvement Bonds, Series 2019A	51,850	51,850
Hospital Improvement Revenue and Improvement Bonds, Series 2019B	92,150	92,150
Hospital Revenue Refunding and Improvement Bonds, Series 2017A	93,290	93,290
Hospital Revenue Refunding and Improvement Bonds, Variable Rate Demand, Series 2017B	44,685	45,070
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2016A	—	5,585
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2016B	—	24,310
Hospital Revenue Refunding Bonds, Series 2016C	120,575	123,525
Hospital Improvement Revenue Bonds, Series 2015A	75,000	75,000
Hospital Improvement Revenue Bonds, Variable Rate Demand, Series 2015B	25,000	25,000
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2014A	5,525	7,290
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2014B	—	45,580
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2013A	28,985	30,835
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2013B	11,510	12,945
Hospital Improvement Revenue Bonds, Series 2012A	—	60,845
Hospital Improvement Revenue Bonds, Variable Rate Demand, Series 2008B	42,300	42,645
Andelyn term loan	75,000	75,000
Finance lease obligations	51,809	1,340
Total long-term debt, including current portion	1,298,459	961,185
Bond discounts, premium and issuance cost – net	16,381	23,972
Less current portion of bonds and finance lease obligations	(83,718)	(81,107)
	<u>\$ 1,231,122</u>	<u>\$ 904,050</u>

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **8. Long-Term Debt (continued)**

In May 2022, the Hospital issued \$300,000,000 of Taxable Bonds (the 2022A Bonds). The 2022A Bonds consisted of \$300,000,000 term bonds due in 2052. The term bonds bear annual interest at 4.56%. The 2022A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2022, the County of Franklin, Ohio (the County) issued \$66,925,000 of Hospital Improvement Revenue Bonds (the 2022B Bonds). The bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments, beginning on May 1, 2022, and ending on May 1, 2042. The 2022B Bonds bear annual interest at a variable rate, which was 3.65% as of December 31, 2022, payable monthly. The 2022B Bonds were issued for the purpose of refunding portions of the 2012A and 2016A Bonds.

In May 2022, the County issued \$67,955,000 of Hospital Improvement Revenue Bonds (the 2022C Bonds). These bonds were purchased by a bank to which Nationwide Children's makes varying principal payments beginning on May 1, 2023 and ending on May 1, 2029. On May 1, 2029 (expiration date of the bank purchase agreement), \$48,030,000 of unpaid principal will remain outstanding. The bonds bear annual interest at an adjustable rate, which was 3.70% as of December 31, 2022, payable monthly. The 2022C Bonds were issued for the purpose of refunding portions of the 2014B and 2016B Bonds. As a result of this refunding and the 2022B Bonds refunding, the Hospital recorded a gain of \$4,540,000 in non-operating gains – net on in the accompanying consolidated statement of operations and changes in net assets for the year-ended December 31, 2022.

In October 2020, the County issued \$148,925,000 of Hospital Improvement Revenue Bonds (the 2020 Bonds). The 2020 Bonds consisted of \$148,925,000 term bonds due in 2050. The term bonds are taxable and bear annual interest at 2.88%. The 2020 Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In November 2019, the County issued \$51,850,000 of Hospital Improvement Revenue Bonds (the 2019A Bonds). The 2019A Bonds consisted of \$51,850,000 term bonds due in 2048. The term bonds bear annual interest at 5%. The 2019A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **8. Long-Term Debt (continued)**

In November 2019, the County issued \$92,150,000 of Hospital Improvement Revenue Bonds (the 2019B Bonds). The 2019B Bonds consisted of \$92,150,000 term bonds due in 2050. The term bonds are taxable and bear annual interest at 3.38%. The 2019B Bonds were issued for the primary purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and a portion of the proceeds were used to fund an interest rate swap termination payment.

In November 2017, the County issued \$93,290,000 of Hospital Revenue Refunding and Improvement Bonds (the 2017A Bonds). The 2017A Bonds consisted of \$68,825,000 serial bonds, maturing in varying amounts from 2028 through 2039; \$12,935,000 of term bonds due in 2044; and \$11,530,000 of term bonds due in 2047. The serial bonds bear annual interest at rates ranging from 3.125% to 5%. The term bonds due in 2044 and 2047 bear annual interest at 4%. The 2017A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and for the current refunding of a portion of the 2008D bonds.

In November 2017, the County issued \$46,150,000 of Hospital Revenue Refunding and Improvement Bonds (the 2017B Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments beginning on November 1, 2018, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. As of November 1, 2019, the bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments each year, ending on November 1, 2052. The bonds bear annual interest at an adjustable rate, which was 3.66% and 0.13% at December 31, 2022 and 2021, respectively. The 2017B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and for the current refunding of a portion of the 2008D bonds.

In April 2016, the County issued \$47,670,000 of Hospital Revenue Refunding Bonds (the 2016A and 2016B Bonds). These bonds were purchased by a bank to which Nationwide Children's makes varying principal payments beginning on May 1, 2017 and ending on May 1, 2026. The bonds bear annual interest at an adjustable rate, which was 0.57% as of December 31, 2021, payable monthly. The 2016A and 2016B Bonds were issued for the purpose of current refunding of the 2008C and 2008F Bonds.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **8. Long-Term Debt (continued)**

In November 2016, the County issued \$129,290,000 of Hospital Revenue Refunding Bonds (the 2016C Bonds). The 2016C Bonds consisted of \$53,010,000 and \$55,960,000 serial bonds as of December 31, 2022 and 2021, respectively, maturing in increasing amounts from 2019 through 2036; \$9,140,000 term bonds due in 2031, and \$58,425,000 term bonds due in 2040. The serial bonds bear interest at annual rates ranging from 3.25% to 5%. The term bonds due in 2031 and 2040 bear annual interest at 5% and 4%, respectively. The 2016C Bonds were issued for the purpose of advance refunding portions of the 2008A and 2009 Bonds.

In May 2015, the County issued \$75,000,000 of Hospital Improvement Revenue Bonds (the 2015A Bonds). The bonds consisted of \$75,000,000 of term bonds due in 2045. The term bonds bear annual interest at 4%. The 2015A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2015, the County issued \$25,000,000 of Hospital Improvement Revenue Bonds (the 2015B Bonds). The bonds mature in 2045, but are subject to redemption prior to maturity under various scenarios. The 2015B bonds bear annual interest at a variable rate, which was 3.61% and 0.001% as of December 31, 2022 and 2021, respectively, payable monthly. Since the 2015B Bonds are remarketed weekly, they are classified within current portion of long-term debt in the consolidated balance sheets. They were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2015, the County issued \$17,225,000 of Hospital Revenue Refunding Bonds (the 2014A Bonds). As of November 1, 2019, the bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments each year, ending on May 1, 2025. The bonds bear annual interest at an adjustable rate, which was 3.660% and 0.001% as of December 31, 2022 and 2021, respectively, payable monthly.

In May 2015, the County issued \$45,580,000 of Hospital Revenue Refunding Bonds (the 2014B Bonds). These bonds were purchased by a bank and no principal payments are due during the term of the agreement. The bonds bear annual interest at an adjustable rate, which was 0.59% as of December 31, 2021, payable monthly.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **8. Long-Term Debt (continued)**

In June 2013, the County issued \$44,155,000 of Hospital Revenue Refunding Bonds (the 2013A Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning November 1, 2013, and ending November 1, 2019, at which time the bank purchase agreement was terminated. As of November 1, 2019, the bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments each year, ending on November 1, 2036. The 2013A Bonds bear interest at an annual adjustable rate, which was 3.66% and 0.001% as of December 31, 2022 and 2021, respectively, payable monthly.

In June 2013, the County issued \$22,830,000 of Hospital Revenue Refunding Bonds (the 2013B Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning on May 1, 2014, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. As of November 1, 2019, the bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments each year, ending on November 1, 2029. The 2013B Bonds bear annual interest at an adjustable rate, which was 3.66% and 0.001% as of December 31, 2022 and 2021, respectively, payable monthly.

In May 2012, the County issued \$75,000,000 of Hospital Improvement Revenue Bonds (the 2012A Bonds). The 2012A Bonds consisted of \$10,845,000 of serial bonds as of December 31, 2021, maturing in varying amounts through 2027, and \$50,000,000 term bonds due in 2042. The serial bonds bear annual interest at rates ranging from 3% to 5% as of December 31, 2021. The term bonds bear annual interest at 5%. The 2012A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2008, the County issued \$45,000,000 of Hospital Improvement Revenue Bonds (the 2008B Bonds). The bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments, beginning on November 1, 2013, and ending on November 1, 2040. The 2008B Bonds bear annual interest at a variable rate, which was 3.61% and 0.001% as of December 31, 2022 and 2021, respectively, payable monthly. Since the 2008B Bonds are remarketed weekly, they are classified within the current portion of long-term debt in the consolidated balance sheets. The 2008B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **8. Long-Term Debt (continued)**

The owners of the 2022B Bonds have the option to demand payment of their outstanding bonds. On May 1, 2022, Nationwide Children's entered into Stand-by Bond Purchase Agreement (the Agreement) for this bond issuance with a bank which requires the remarketing agent to utilize its best efforts to remarket any such bonds that may be tendered for payment. In the event any such bonds cannot be remarketed, the Agreement provides that the bank will provide payment for the bonds tendered. Should certain events occur, the amounts due to the bank will be converted to a term loan, for which Nationwide Children's has an obligation to make payment over four years, in quarterly payments, plus any accrued interest.

The owners of the 2017B, 2014A, 2013A, and 2013B Bonds have the option to demand payment of their outstanding bonds. On November 1, 2019, Nationwide Children's entered into Stand-by Bond Purchase Agreements (the Agreements) for each of these bond issues with a bank which require the remarketing agent to utilize its best efforts to remarket any such bonds that may be tendered for payment. In the event any such bonds cannot be remarketed, the Agreements provide that the bank will provide payment for the bonds tendered. Should certain events occur, the amounts due to the bank will be converted to a term loan, for which Nationwide Children's has an obligation to make payment over three years, in quarterly payments, plus any accrued interest.

The owners of the 2015B and 2008B Bonds have the option to demand payment of their outstanding bonds. Should the remarketing agent be unsuccessful in remarketing these bonds, Nationwide Children's is providing its own liquidity as the repayment source to the bondholders.

Interest on the 2022A Bonds, 2020 Bonds, 2019A Bonds, 2019B Bonds, 2017A Bonds, 2016C Bonds, and 2015A Bonds is payable semi-annually on May 1 and November 1 of each year.

On March 18, 2021 (the Effective Date), Andelyn entered into a Credit Agreement with an unrelated third party and its affiliates (the Lenders). Pursuant to the Credit Agreement, Andelyn entered into a senior secured Term Loan for \$75,000,000 which matures in September 2027. The Term Loan bears interest equal to the greater of the prime rate, Federal Funds Effective Rate or the Eurodollar Rate plus 1.00% plus an applicable margin. The interest rates in effect were 12.74% and 9.00% as of December 31, 2022 and 2021, respectively. The Term Loan is secured by substantially all of the assets of Andelyn. The Credit Agreement contains customer financial and nonfinancial covenants that Andelyn must comply with until all loans and other obligations are paid in full. No financial covenants were in place as of December 31, 2022. Interest expense, net of capitalized interest, incurred on the Term Loan amounted to \$441,000 for the year ended December 31, 2022 and is included in interest expense in the consolidated statement of operations



## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **8. Long-Term Debt (continued)**

and changes in net assets. The Term Loan requires no periodic principal payments and is due in full at maturity. As of December 31, 2022, there are no payments due under the Term Loan for the years ended December 31, 2023 through December 31, 2026.

Nationwide Children's made interest payments on long-term debt of \$33,001,000 and \$29,783,000 during 2022 and 2021, respectively.

In connection with the issuance of the Bonds, the County acquired title to substantially all of the Hospital's facilities and real property. The facilities and real property are, in turn, being leased to the Hospital through 2052, the latest mandatory retirement date of the Bonds, with payment terms equal to the debt service requirements of the Bonds. A provision of the lease grants an option to the Hospital to purchase the facilities for a nominal sum after provision has been made to retire the Bonds. The Hospital's facilities and real property are accounted for as a finance lease in the consolidated balance sheets.

Provisions of the Bonds require Nationwide Children's to, among other things, comply with certain financial ratios, restrict additional encumbrances, restrict the sale or acquisition of certain assets, or merge with another entity. As of December 31, 2022 and 2021, Nationwide Children's was in compliance with its debt covenants.

Aggregate scheduled maturities of long-term debt in each of the following five years are: 2023 – \$14,525,000; 2024 – \$14,995,000; 2025 – \$15,505,000; 2026 – \$16,240,000 and 2027 – \$16,810,000.

#### **9. Leases**

Nationwide Children's has operating and finance leases for real estate, personal property and equipment. Nationwide Children's determines if an arrangement is a lease at the inception of a contract. Operating lease right-of-use assets are included in other long-term assets and operating lease liabilities are included in other current and long-term liabilities in the consolidated balance sheets. Nationwide Children's had right-of-use assets and lease liabilities for operating leases totaling approximately \$29,428,000 and \$31,688,000, respectively, at December 31, 2022. Nationwide Children's had right-of-use assets and lease liabilities for operating leases totaling approximately \$20,938,000 and \$22,118,000, respectively, at December 31, 2021. Finance lease right-of-use assets are included in property and equipment and the related lease liabilities are included in current portion of long-term debt and long-term debt in the consolidated balance sheets,

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 9. Leases (continued)

totaling approximately \$53,726,000 and \$51,809,000, respectively, at December 31, 2022. Nationwide Children's had finance lease right-of-use assets and lease liabilities totaling approximately \$1,377,000 and \$1,340,000, respectively, at December 31, 2021. Leases with an initial term of twelve months or less are not recorded in the consolidated balance sheets. Nationwide Children's has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component.

Right-of-use assets represent Nationwide Children's right to use an underlying asset during the lease term and lease liabilities represent Nationwide Children's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date based on the net present value of fixed lease payments over the lease term. Nationwide Children's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of the operating leases do not provide an implicit rate, Nationwide Children's uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Nationwide Children's considers recent debt issuances, as well as publicly available data for instruments with similar characteristics, when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term.

Operating expenses for the leasing activity of Nationwide Children's as lessee for the years ended December 31 are as follows:

<b>Classification</b>		<b>2022</b>	<b>2021</b>
		<i>(In Thousands)</i>	
Operating lease expense	Other expense	\$ 8,113	\$ 6,575
Financing lease interest	Interest expense	681	70
Financing lease amortization	Depreciation and amortization	2,600	135
Total lease cost		<u>\$ 11,394</u>	<u>\$ 6,780</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

**9. Leases (continued)**

Supplemental cash flow information for the years ended December 31 is as follows:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 7,824	\$ 6,766
Operating cash flows from finance leases	681	70
Financing cash flows from finance leases	1,879	123
Total	<u>\$ 10,384</u>	<u>\$ 6,959</u>

The aggregate future lease payments for operating and finance leases as of December 31, 2022 are as follows:

	<b>Operating</b>	<b>Finance</b>
	<i>(In Thousands)</i>	
2023	\$ 7,895	\$ 3,114
2024	6,576	3,208
2025	5,202	3,234
2026	4,796	3,233
2027	4,359	3,295
Thereafter	31,280	45,468
Total lease payments	60,108	61,552
Less: imputed interest	(28,420)	(9,743)
Present value of lease liabilities	<u>\$ 31,688</u>	<u>\$ 51,809</u>

Average lease terms and discount rates as of December 31 are as follows:

	<b>2022</b>	<b>2021</b>
Weighted-average remaining lease term (years):		
Operating leases	5.3	5.9
Finance leases	19.9	7.7
Weighted-average discount rate:		
Operating leases	3.9%	4.9%
Finance leases	1.7%	5.0%

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 10. Derivatives

Nationwide Children's has entered into various interest rate swap agreements with the intent of mitigating Nationwide Children's cash flow risk relating to changes in the variable interest rates of its bonds as listed within the following table. Under the swap agreements, Nationwide Children's pays interest at fixed rates (see table below) and receives interest at variable rates. Net interest paid or received under the swap agreements is included in interest expense. The following schedule outlines the terms and fair values of the interest rate swap agreements for the years ended December 31.

	<b>Notional Amount at December 31, 2022</b>	<b>Effective Date</b>	<b>Termination Date</b>	<b>Fixed Annual Rate</b>	<b>2022</b>	<b>2021</b>
Series 2008B	\$ 42,300	05-01-2008	11-01-2040	4.13%	\$ (3,940)	\$ (15,086)
Series 2017B	44,520	11-01-2010	11-01-2033	3.22	(2,227)	(8,573)
Series 2013A	3,645	11-01-2006	11-01-2025	3.66	(42)	(339)
Series 2013B	11,440	09-23-2005	05-01-2029	3.19	(115)	(1,148)
Series 2014A	5,525	05-01-2015	05-01-2025	1.78	87	(174)
Series 2022B	59,775	05-01-2022	11-01-2042	1.78	9,087	(1,611)
Series 2022C	45,580	05-01-2015	05-01-2035	2.06	1,335	(4,890)
Series 2022B	4,245	12-12-2002	11-01-2025	3.28	(26)	(357)
Series 2022C	22,270	09-01-2005	05-01-2031	3.57	(733)	(3,197)
					<u>\$ 3,426</u>	<u>\$ (35,375)</u>

In January 2009, Nationwide Children's entered into a speculative interest rate swap. The initial notional amount of this interest rate swap agreement was \$45,000,000, and the effective date of the transaction was January 1, 2011. Nationwide Children's pays interest based on 100% of the monthly Securities Industry and Financial Markets Association (SIFMA) Municipal Swap Index, and receives interest based on 100.89% of the 3-month LIBOR. The notional amount was \$42,300,000 and \$42,645,000 at December 31, 2022 and 2021, respectively. The fair value was \$2,393,000 and \$1,127,000 at December 31, 2022 and 2021, respectively, and the asset is netted against the interest rate swap liability in the consolidated balance sheets.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 10. Derivatives (continued)

In December 2018, Nationwide Children's entered into a speculative interest rate swap agreement. The initial and current notional amount of this interest rate swap agreement was \$100,000,000, and the effective date of the transaction was January 1, 2020. Nationwide Children's pays interest based on 67% of 1-month LIBOR, and receives interest based on 55.33% of 10-year LIBOR. The fair value was \$(2,000,000) and \$1,525,000 at December 31, 2022 and 2021, respectively, and is included in the interest rate swap liability in the consolidated balance sheets.

Nationwide Children's has recorded the fair value of the interest rate swap agreements of \$3,819,000 and \$(32,723,000) as a long-term liability in the consolidated balance sheets as of December 31, 2022 and 2021, respectively. The change in fair market value of the interest rate swap agreements of \$36,542,000 and \$14,035,000 in 2022 and 2021, respectively, is included in other nonoperating gains – net.

The following table presents the fair value of derivative instruments, location of the related instruments in the consolidated balance sheets and the related notional amounts of the derivative instruments as of December 31:

<b>Derivative Liabilities</b>	
<b>Balance Sheet Classification</b>	<b>Fair Value</b>
<i>(In Thousands)</i>	
Derivatives not designated as hedging instruments:	
Interest rate contracts – 2022	Other long-term liabilities    \$ <b>(3,819)</b>
Interest rate contracts – 2021	Other long-term liabilities    \$        32,723

Nationwide Children's made net payments on interest rate swaps of approximately \$4,127,000 and \$5,917,000 during 2022 and 2021, respectively, which are recorded within interest expense, net of the change in accruals for these payments.

### 11. Defined Benefit Plan

Nationwide Children's has a defined benefit pension plan (the Plan) for employees who meet certain requirements as to age and length of service. Nationwide Children's funding policy is to make at least the minimum annual contributions required by applicable regulations.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 11. Defined Benefit Plan (continued)

The Plan was curtailed effective December 31, 1996, with respect to: (1) any employee under the age of 45, (2) any employee over the age of 45 who was not fully vested in his or her accrued benefit under the Plan, and (3) any other participant who elected to cease his or her participation in the Plan (affected participants). At that time, the accrued benefits of each affected participant became fully vested and non-forfeitable.

The following tables set forth the change in benefit obligation, change in plan assets, funded status, and components of net periodic benefit cost of the Plan:

	<b>December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
<b>Change in benefit obligation</b>		
Benefit obligation, beginning of the year	\$ 84,998	\$ 91,730
Service cost	190	340
Interest cost	1,981	1,724
Actuarial losses	(14,288)	(3,184)
Benefits paid	(6,015)	(5,612)
Benefit obligation, end of year	66,866	84,998
<b>Change in plan assets</b>		
Fair value of plan assets, beginning of the year	83,281	77,450
Actual return on plan assets	(12,071)	10,383
Employer contributions	760	1,060
Benefits paid	(6,015)	(5,612)
Fair value of plan assets, end of the year	65,955	83,281
Unfunded	\$ (911)	\$ (1,717)

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

**11. Defined Benefit Plan (continued)**

	<b>Year Ended December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
<b>Components of net periodic pension cost</b>		
Service cost	\$ 190	\$ 340
Interest cost	1,981	1,724
Expected return on plan assets	(4,963)	(4,764)
Amortization of net loss	1,422	1,793
Net periodic pension credit	<u>\$ (1,370)</u>	<u>\$ (907)</u>

Weighted average assumptions used to determine benefit obligations as of December 31 are as follows:

	<b>2022</b>	<b>2021</b>
Discount rate	<b>4.86%</b>	2.40%
	<b>Pri-2012 with fully generational projection using scale MP-2021</b>	Pri-2012 with fully generational projection using scale MP-2021
Mortality		

Weighted average assumptions used to determine net periodic pension cost for the years ended December 31 are as follows:

	<b>2022</b>	<b>2021</b>
Discount rate	<b>2.40%</b>	1.94%
Expected return on plan assets	<b>7.00%</b>	7.00%
	<b>2022 PPA optional combined mortality</b>	2021 PPA optional combined mortality
Mortality		

Included as a reduction in net assets without donor restrictions are actuarial losses of \$23,772,000 and \$22,437,000 at December 31, 2022 and 2021, respectively, which will be recognized in net periodic pension cost in future periods.

The accumulated benefit obligation of the Plan at December 31, 2022 and 2021 was \$66,866,000 and \$84,998,000, respectively.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 11. Defined Benefit Plan (continued)

Expected benefit payments for the next ten years are: 2023 – \$6,306,000; 2024 – \$6,209,000; 2025 – \$6,094,000; 2026 – \$5,966,000; 2027 – \$5,846,000 and 2028 through 2032 – \$26,563,000.

The allocation of Plan assets by major category as a percentage of total Plan assets is set forth in the following table:

	December 31			
	2022		2021	
	Actual	Target	Actual	Target
Domestic equities	54%	43%	56%	43%
International equities	10	7	9	7
Fixed income and cash equivalents	36	50	35	50
	100%	100%	100%	100%

The target asset allocations are designed to match expected returns with the time horizon for the liabilities of the Plan, and are periodically reviewed and approved by the Finance Committee of the Board of Directors. The use of derivatives is currently not permitted by the Plan's investment policy. The expected long-term rate of return assumption is based upon historical returns and management's belief that future returns will approximate historical returns over a long-term time horizon.



Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

**11. Defined Benefit Plan (continued)**

The fair value of plan assets at December 31 is as follows:

	<b>2022</b>			
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total Fair Value</b>
	<i>(In Thousands)</i>			
Cash and cash equivalents	\$ 4,662	\$ —	\$ —	\$ 4,662
Fixed income:				
U.S. Treasury bonds and notes	—	7,624	—	7,624
U.S. Government agencies	—	1,292	—	1,292
Corporate obligations	—	10,351	—	10,351
Equities – mutual funds:				
Domestic large-cap indexed	25,105	—	—	25,105
Domestic mid-cap indexed	4,252	—	—	4,252
Domestic small-cap indexed	6,286	—	—	6,286
International	6,383	—	—	6,383
Total	\$ 46,688	\$ 19,267	\$ —	\$ 65,955
	<b>2021</b>			
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total Fair Value</b>
	<i>(In Thousands)</i>			
Cash and cash equivalents	\$ 5,420	\$ —	\$ —	\$ 5,420
Fixed income:				
U.S. Treasury bonds and notes	—	10,536	—	10,536
U.S. Government agencies	—	1,325	—	1,325
Corporate obligations	—	11,539	—	11,539
Equities – mutual funds:				
Domestic large-cap indexed	33,558	—	—	33,558
Domestic mid-cap indexed	5,589	—	—	5,589
Domestic small-cap indexed	7,704	—	—	7,704
International	7,610	—	—	7,610
Total	\$ 59,881	\$ 23,400	\$ —	\$ 83,281

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### **11. Defined Benefit Plan (continued)**

Fair value methodologies for Level 1, 2 and 3 are consistent with the inputs described in Note 6.

Nationwide Children's will not make a contribution to the Plan during 2022. Nationwide Children's estimates that it will not amortize any of the net actuarial losses from net assets without donor restrictions into net periodic pension cost during 2023.

#### **12. Defined Contribution Plans**

Effective January 1, 1997, the Matching Plan was amended and renamed as the Nationwide Children's Hospital Employee Defined Contribution Plan (Defined Contribution Plan). The Defined Contribution Plan includes both an employee matching contribution and an additional employer defined contribution and contains provisions specifically permitting affected participants to transfer distributions received from the revised pension plan. The employer defined contribution is based upon certain percentages of employees' wages, which are determined based upon length of service and income levels.

Nationwide Children's provides a 403(b) matching contribution plan for essentially all employees who have met specified service requirements. Under the plan, Nationwide Children's matches 50% of the first 3% of salaries contributed by each participant, up to a maximum of 1.5% of the participant's salary.

Nationwide Children's incurred expenses related to these plans totaled \$63,092,000 and \$55,220,000 during 2022 and 2021, respectively.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 13. Property and Equipment

Details of property and equipment are summarized as follows as of December 31:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Land and land improvements	\$ 96,046	\$ 95,690
Buildings and improvements	1,756,679	1,686,697
Equipment	510,338	459,822
Construction-in-progress	443,206	182,338
	<u>2,806,269</u>	<u>2,424,547</u>
Allowances for depreciation	(935,181)	(827,227)
	<u><u>\$ 1,871,088</u></u>	<u><u>\$ 1,597,320</u></u>

The ranges of useful lives associated with the following categories of property and equipment are as follows: land improvements – 8–15 years; buildings and improvements – 10–30 years; equipment – 5–20 years.

Outstanding commitments for the purchase of property and equipment were approximately \$58,720,000 and \$37,141,000 at December 31, 2022 and 2021, respectively. Nationwide Children's expects to pay outstanding commitments at December 31, 2022 during 2023, using funds from operations and fundraising contributions, and proceeds from the 2022A Bonds.

### 14. Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of estimated future cash flows. The annual discounts applied to these amounts are computed by using an applicable annual interest rate to the year in which the promise is received, which is up to 4.5%.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 14. Pledges Receivable (continued)

The following is a summary of pledges receivable and the anticipated schedule of their receipt, for the years ended December 31:

	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Gross unconditional pledges receivable	\$ 41,772	\$ 26,635
Less:		
Allowance for doubtful pledges	(952)	(796)
Unamortized discount	(1,716)	(2,265)
Net unconditional pledges receivable	<u>\$ 39,104</u>	<u>\$ 23,574</u>
Amounts due in:		
Less than one year	\$ 15,194	\$ 12,616
One to five years	25,693	12,203
Greater than five years	885	1,816
Total	<u>\$ 41,772</u>	<u>\$ 26,635</u>

### 15. Functional Expenses

Nationwide Children's provides a complete range of preventive, diagnostic, therapeutic and rehabilitative pediatric health services to residents within a 34-county area encompassing central, southern and southeastern Ohio. The tables below present expenses related to providing these services by both nature and function for the years ended December 31:

	<b>2022</b>					
	<b>Healthcare Services</b>	<b>Management and General</b>	<b>Foundation</b>	<b>Research</b>	<b>Education</b>	<b>Total</b>
	<i>(In Thousands)</i>					
Salaries and benefits	\$ 932,536	\$ 358,905	\$ 5,204	\$ 142,486	\$ 37,159	\$ 1,476,290
Claims expense	898,096	—	—	—	—	898,096
Supplies	322,517	14,865	75	36,689	606	374,752
Purchased services	146,263	73,202	3,161	20,554	325	243,505
Interest	597	25,885	—	—	—	26,482
Depreciation and amortization	43,730	58,689	—	10,916	1,233	114,568
Other	97,928	152,795	1,074	18,541	1,935	272,273
Total operating expenses	<u>\$ 2,441,667</u>	<u>\$ 684,341</u>	<u>\$ 9,514</u>	<u>\$ 229,186</u>	<u>\$ 41,258</u>	<u>\$ 3,405,966</u>

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 15. Functional Expenses (continued)

	2021					
	Healthcare Services	Management and General	Foundation	Research	Education	Total
	<i>(In Thousands)</i>					
Salaries and benefits	\$ 829,826	\$ 319,062	\$ 4,683	\$ 122,334	\$ 34,139	\$ 1,310,044
Claims expense	942,577	—	—	—	—	942,577
Supplies	292,990	11,735	99	35,400	426	340,650
Purchased services	74,892	64,818	2,724	21,281	284	163,999
Interest	—	31,640	—	—	—	31,640
Depreciation and amortization	42,446	56,330	—	9,872	1,130	109,778
Other	102,936	139,897	876	11,110	1,653	256,472
Total operating expenses	<u>\$ 2,285,667</u>	<u>\$ 623,482</u>	<u>\$ 8,382</u>	<u>\$ 199,997</u>	<u>\$ 37,632</u>	<u>\$ 3,155,160</u>

The consolidated financial statements report certain categories of expenses that are attributable to more than one supporting function. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries and benefits, which are allocated on a per full-time equivalent basis, and depreciation, which is allocated based on square footage.

### 16. Financial Assets and Liquidity Availability

As of December 31, 2022 and 2021, Nationwide Children's had a working capital surplus of \$657,432,000 and \$579,871,000, respectively.

Financial assets available for general expenditure within one year of the consolidated balance sheet date for the years ended December 31 consist of the following:

	2022	2021
	<i>(In Thousands)</i>	
Financial assets:		
Cash and cash equivalents	\$ 432,579	\$ 307,740
Short-term investments	50,776	—
Patient accounts receivable	368,076	367,423
Other assets	182,821	149,112
Assets limited as to use:		
Board-designated capital improvement	69,472	76,102
Board-designated other	3,386,603	3,781,132
Financial assets available for general expenditures within one year	<u>\$ 4,490,327</u>	<u>\$ 4,681,509</u>

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Notes to Consolidated Financial Statements (continued)

#### 16. Financial Assets and Liquidity Availability (continued)

Nationwide Children's has certain board-designated assets limited as to use which are available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. Nationwide Children's has other assets limited as to use for donor-restricted purposes, debt service and for the professional liability captive insurance program. These assets limited as to use are not available for general expenditure within the next year and are not reflected in the amounts above. As part of Nationwide Children's liquidity management plan, cash in excess of daily requirements is invested in short-term investments and money market funds.

#### 17. Concentration of Credit Risk

In most cases, Nationwide Children's grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of the Nationwide Children's receivables based on receivables before price concessions from patients and third-party payors was as follows:

	<b>December 31</b>	
	<b>2022</b>	<b>2021</b>
Medicaid	<b>40%</b>	36%
Commercial	<b>42</b>	48
Other third-party payors	<b>10</b>	9
Patients' responsibility	<b>8</b>	7
	<b>100%</b>	100%

#### 18. Net Assets with Donor Restrictions

Net assets with donor restrictions are those whose use by Nationwide Children's has been limited by donors to a specific time period or purpose or those that have been restricted by donors to be maintained by Nationwide Children's in perpetuity. Investment return is allocated to net assets

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 18. Net Assets with Donor Restrictions (continued)

without donor restrictions and net assets with donor restrictions based on the respective net asset balances and the wishes of the donor. The nature and amounts of the net assets with donor restrictions are as follows:

	<b>December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Net assets with donor restrictions:		
Program support	\$ 335,939	\$ 314,460
Research	87,267	95,655
	<u>\$ 423,206</u>	<u>\$ 410,115</u>

Nationwide Children's endowment consists of approximately 200 individual, donor-restricted, funds established for various purposes. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. Nationwide Children's classifies as net assets with donor restrictions: (1) the original value of gifts donated to the permanent endowment, (2) the original value of subsequent gifts to the permanent endowment, and (3) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulations are added to the fund. Nationwide Children's considers the following factors in making a determination to appropriate or accumulate donor-restricted funds: (1) the duration and preservation of the fund, (2) the purposes of the organization and the donor-restricted endowment fund, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, (6) other resources of the organization, and (7) investment policies of the organization.

To satisfy its long-term rate-of-return objectives, Nationwide Children's relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). A diversified asset allocation is targeted that places a greater emphasis on equity-based investments to achieve long-term return objectives within prudent risk considerations. Nationwide Children's expects its endowment funds, over time, to provide an average rate of return of approximately 7% annually. Actual returns in any given year may vary from this amount.

# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to Consolidated Financial Statements (continued)

### 18. Net Assets with Donor Restrictions (continued)

Nationwide Children's has a policy of appropriating for distribution each year 5% of the spendable balance of its endowment. In establishing this policy, Nationwide Children's considered the long-term expected return on its endowment. Accordingly, over the long-term, it is expected this spending policy will allow its endowment to grow at an average of 2% annually. This is consistent with Nationwide Children's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term, as well as to provide additional real growth through new gifts and investment return.

Nationwide Children's had the following donor-restricted endowment-related activities:

	<b>Change in Endowment Net Assets with Donor Restrictions for the Year Ended December 31</b>	
	<b>2022</b>	<b>2021</b>
	<i>(In Thousands)</i>	
Endowment net assets, beginning of year	\$ 265,100	\$ 239,092
Investment return:		
Investment income	7,683	10,977
Unrealized (losses) gains	(33,332)	16,249
Total investment return	(25,649)	27,226
Contributions	6,214	6,962
Appropriation of endowment assets for expenditure	(6,756)	(8,180)
Endowment net assets, end of year	<u>\$ 238,909</u>	<u>\$ 265,100</u>



Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

**19. Subsequent Events**

Nationwide Children's has evaluated and disclosed any subsequent events through April 26, 2023, which is the date the consolidated financial statements were issued. No subsequent events were identified that required recognition or disclosure in the consolidated financial statements.

## Supplementary Information

**NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**

**Fiscal Period 1/1/2022 - 12/31/2022**

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
<b>DEPARTMENT OF AGRICULTURE</b>									
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	GR102924	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR102924		\$5,109	\$5,109	RESEARCH AND DEVELOPMENT	\$82,409,498
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	ORD NO. 2017-2020	COLUMBUS HEALTH DEPARTMENT	ORD NO. 2017-2020		-\$1,085	\$904,429	N/A	\$0
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	PO294561/ORD NO. 2315-2021	COLUMBUS HEALTH DEPARTMENT	PO294561/ORD NO. 2315-2021		\$755,336	\$904,429	N/A	\$0
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	ORD #2447-2022	COLUMBUS HEALTH DEPARTMENT	ORD #2447-2022		\$150,178	\$904,429	N/A	\$0
<b>TOTAL DEPARTMENT OF AGRICULTURE</b>						<u>\$909,538</u>			
<b>DEPARTMENT OF DEFENSE</b>									
SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	12.351	60075912	THE OHIO STATE UNIVERSITY	60075912		-\$847	-\$847	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810546				-\$38	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810518			\$5,580	\$72,398	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810547			\$10,984	\$60,155	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910371				\$1,716	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010340			\$22,893	\$124,089	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH210278			\$1,350	\$116,969	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2210597				\$148,463	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH17-1-0420				-\$13,283	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	NTRAP-18-04	NATIONAL TRAUMA INSTITUTE	NTRAP-18-04		-\$40	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	417439/URFAO: GR510697	UNIVERSITY OF ROCHESTER	417439/URFAO: GR510697		-\$14	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	417439/URFAO: GR510697	UNIVERSITY OF ROCHESTER	417439/URFAO: GR510697		\$233,218	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	2005081209	THE JOHNS HOPKINS UNIVERSITY	2005081209		\$41,830	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	GR111789 / PO SPC-1000005884	THE OHIO STATE UNIVERSITY	GR111789 / PO SPC-1000005884		\$13,849	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	124560	NEW YORK MEDICAL COLLEGE	124560		\$20,622	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	124560	NEW YORK MEDICAL COLLEGE	124560		\$6,612	\$826,546	RESEARCH AND DEVELOPMENT	\$82,409,498
<b>TOTAL DEPARTMENT OF DEFENSE</b>						<u>\$40,807</u>	<u>\$825,699</u>		
<b>DEPARTMENT OF JUSTICE</b>									
SERVICES FOR TRAFFICKING VICTIMS	16.320	2019-MU-BX-0156	OFFICE FOR VICTIMS OF CRIME	2019-MU-BX-0156	\$5,728	\$178,455	\$178,455	RESEARCH AND DEVELOPMENT	\$82,409,498
CRIME VICTIM ASSISTANCE	16.575	2018-VOCA-109853871	CRIME VICTIMS ASSITANCE	2018-VOCA-109853871	\$8,531	\$8,531	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2021-VOCA-133977029	CRIME VICTIMS ASSITANCE	2021-VOCA-133977029		-\$578	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022-VOCA-134719414	CRIME VICTIMS ASSITANCE	2022-VOCA-134719414		\$131,404	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022-SVAA-134719417	CRIME VICTIMS ASSITANCE	2022-SVAA-134719417		\$7,853	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022-SVAA-134716708	CRIME VICTIMS ASSITANCE	2022-SVAA-134716708	\$56,818	\$56,818	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022-VOCA-134716701	CRIME VICTIMS ASSITANCE	2022-VOCA-134716701	\$81,820	\$81,820	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022DVF42	CRIME VICTIMS ASSITANCE	2022DVF42		\$32,032	\$355,849	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2023-VOCA-135104760	CRIME VICTIMS ASSITANCE	2023-VOCA-135104760		\$37,969	\$355,849	N/A	\$0
DRUG COURT DISCRETIONARY GRANT PROGRAM	16.585	RESOLUTION 20210502	MONTGOMERY CNTY JUVENILE COURT	RESOLUTION 20210502		\$2,878	\$2,878	RESEARCH AND DEVELOPMENT	\$82,409,498
GRANTS TO ENCOURAGE ARREST POLICIES AND ENFORCEMENT OF PROTECTION ORDERS PROGRAM	16.590	60-ICIRP-BP	FRANKLIN COUNTY OFFICE OF JUSTICE POLICY AND PROGRAMS	60-ICIRP-BP		\$16,187	\$16,187	RESEARCH AND DEVELOPMENT	\$82,409,498
EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	16.738	2019-JG-E01-6378	OH OFC OF CRIMINAL JUSTICE SVC	2019-JG-E01-6378		\$10,121	\$10,121	RESEARCH AND DEVELOPMENT	\$82,409,498
IMPROVING THE INVESTIGATION AND PROSECUTION OF CHILD ABUSE AND THE REGIONAL AND LOCAL CHILDREN'S ADVOCACY CENTERS	16.758	2018-CI-FX-K003	NATIONAL CHILDREN'S ALLIANCE	2018-CI-FX-K003		\$20,000	\$20,000	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILDREN OF INCARCERATED PARENTS	16.831	303019	FRANKLIN COUNTY OFFICE OF JUSTICE POLICY AND PROGRAMS	303019	\$39,821	\$99,239	\$99,239	N/A	\$0
<b>TOTAL DEPARTMENT OF JUSTICE</b>						<u>\$192,718</u>	<u>\$682,729</u>		

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<b>DEPARTMENT OF TREASURY</b>									
COVID-19 CORONAVIRUS RELIEF FUND	21.019	COVID-19 2020-CARES-78	CRIME VICTIMS ASSISTANCE	2020-CARES-78		\$312	\$312	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19 SAFETY TOWN - CITY OF COLUMBUS	CITY OF COLUMBUS, DEPARTMENT OF NEIGHBORHOODS	SAFETY TOWN - CITY OF COLUMBUS		\$50,000	\$220,275	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	OHIO DEPARTMENT OF MEDICAID	COVID-19		\$170,075	\$220,275	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	OHIO DEPARTMENT OF MEDICAID	COVID-19		\$200	\$220,275	N/A	\$0
<b>TOTAL DEPARTMENT OF TREASURY</b>						<u>\$220,587</u>			
<b>FEDERAL COMMUNICATIONS COMMISSION</b>									
COVID-19 TELEHEALTH PROGRAM	32.006	COVID-19 834	UNIVERSAL SERVICE ADMINISTRATIVE COMPANY (USAC)	834	\$218,613	\$722,609	\$722,609	N/A	\$0
<b>TOTAL FEDERAL COMMUNICATIONS COMMISSION</b>					<u>\$218,613</u>	<u>\$722,609</u>			
<b>NATIONAL SCIENCE FOUNDATION</b>									
BIOLOGICAL SCIENCES	47.074	2120949			\$14,412	\$137,100	\$151,858	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOLOGICAL SCIENCES	47.074	5506-NCH-NSF-9072	THE PENNSYLVANIA STATE UNIVERSITY	5506-NCH-NSF-9072		\$14,758	\$151,858	RESEARCH AND DEVELOPMENT	\$82,409,498
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SUB0000516	PRINCETON UNIVERSITY	SUB0000516		\$25,292	\$25,292	RESEARCH AND DEVELOPMENT	\$82,409,498
<b>TOTAL NATIONAL SCIENCE FOUNDATION</b>					<u>\$14,412</u>	<u>\$177,150</u>			
<b>DEPARTMENT OF EDUCATION</b>									
TRIO UPWARD BOUND	84.047	P047M170582 - 21				\$121,052	\$176,603	N/A	\$0
TRIO UPWARD BOUND	84.047	P047M220591				\$55,551	\$176,603	N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	2218	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	2218		\$946	\$48,255	RESEARCH AND DEVELOPMENT	\$82,409,498
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	2216	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	2216		\$47,309	\$48,255	RESEARCH AND DEVELOPMENT	\$82,409,498
<b>TOTAL DEPARTMENT OF EDUCATION</b>						<u>\$224,858</u>			
<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>									
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	60079488 GR123656	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60079488 GR123656		\$187,798	\$378,131	N/A	\$0
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	SPC-1000006740 / GR127706	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000006740 / GR127706		\$190,333	\$378,131	N/A	\$0
CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION	93.068	ACR	AMERICAN COLLEGE OF RHEUMATOLOGY	ACR		\$3,880	\$3,880	RESEARCH AND DEVELOPMENT	\$82,409,498
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.069	34225	OHIO DEPARTMENT OF HEALTH	34225	\$99,459	\$135,198	\$192,731	RESEARCH AND DEVELOPMENT	\$82,409,498
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.069	34225-A4	OHIO DEPARTMENT OF HEALTH	34225-A4		\$57,533	\$192,731	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	CDC 436 21-22	HEMOPHILIA FOUNDATION OF MICHIGAN	CDC 436 21-22		\$23,452	\$28,863	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	CDC 436 22-23	HEMOPHILIA FOUNDATION OF MICHIGAN	CDC 436 22-23		\$5,411	\$28,863	RESEARCH AND DEVELOPMENT	\$82,409,498
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$37	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$56	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$89,982	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$47,544	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$45,106	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$43,909	\$257,928	N/A	\$0

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	CSP904320-3	OHIO DEPT OF YOUTH SERVICES	CSP904320-3		\$3,151	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	CSP904320-3	OHIO DEPT OF YOUTH SERVICES	CSP904320-3		\$3,195	\$257,928	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	90AP2678NCH	OHIO HEALTH RESEARCH INSTITUTE	90AP2678NCH		\$24,948	\$257,928	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	5R01FD006352-03				\$227,325	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	5R01FD006352-04				\$54,374	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1R01FD007532-01				\$6,803	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	000508836-002	UNIVERSITY OF AL AT BIRMINGHAM	000508836-002		\$15,863	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	123900	NEW YORK MEDICAL COLLEGE	123900		-\$7	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	123900	NEW YORK MEDICAL COLLEGE	123900		\$1,898	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	123903	NEW YORK MEDICAL COLLEGE	123903		\$2,169	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678		-\$6,342	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678		\$6,341	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678		\$28,887	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678		\$13,331	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	GRT-00000248	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000248		\$12,865	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	GRT-00000249	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000249		-\$165	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	12593SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12593SUB		\$104,586	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	A035599	DUKE UNIVERSITY	A035599		\$211,646	\$679,574	RESEARCH AND DEVELOPMENT	\$82,409,498
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MCHB 436 21-22	HEMOPHILIA FOUNDATION OF MICHIGAN	MCHB 436 21-22		\$7,594	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	CASCADE 2022-2023	HEMOPHILIA FOUNDATION OF MICHIGAN	CASCADE 2022-2023		\$7,062	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	CASCADE 2022-2023	HEMOPHILIA FOUNDATION OF MICHIGAN	CASCADE 2022-2023		\$143	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	1 R40MC37541-01-00				\$16,050	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	1 R40MC41749-01-00				\$39,629	\$347,544	RESEARCH AND DEVELOPMENT	\$82,409,498
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60078550	THE OHIO STATE UNIVERSITY	60078550		\$2,411	\$347,544	RESEARCH AND DEVELOPMENT	\$82,409,498
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60079691 / IMPLICIT ICC	THE OHIO STATE UNIVERSITY	60079691 / IMPLICIT ICC		\$2,800	\$347,544	RESEARCH AND DEVELOPMENT	\$82,409,498
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	RPPN	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	RPPN		\$71,729	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	RPPN	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	RPPN		\$38,627	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	GR124424/SPC-1000005299	THE OHIO STATE UNIVERSITY	GR124424/SPC-1000005299		\$98,497	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	GR127800 SPC-1000006745	THE OHIO STATE UNIVERSITY	GR127800 SPC-1000006745		\$54,813	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MCHB 436 22-23	HEMOPHILIA FOUNDATION OF MICHIGAN	MCHB 436 22-23		\$6,661	\$347,544	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	317719	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	317719		\$1,528	\$347,544	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1U01DE030065-01A1			\$35,881	\$333,094	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5U01DE030065-02				\$153,085	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE027091-03			\$97,672	\$365,260	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5R01DE027091-04				\$376,824	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE028296-04				\$230,386	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5R01DE028296-05				\$19,243	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1044863-10	THE UNIVERSITY OF UTAH	1044863-10		\$61,846	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	10044863-10	THE UNIVERSITY OF UTAH	10044863-10		-\$61,883	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	10044863-10	THE UNIVERSITY OF UTAH	10044863-10		\$19,428	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	10044863-10	THE UNIVERSITY OF UTAH	10044863-10		\$55,458	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295		\$1	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295		-\$3,226	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295		\$33,839	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498

**NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)**

**Fiscal Period 1/1/2022 - 12/31/2022**

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA SEATTLE CHILDREN'S RESEARCH INSTITUTE	5113295		\$63,366	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	12282SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12282SUB		\$2,371	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	12282SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12282SUB		\$21,163	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	SITZMAN-20-04	PHOENIX CHILDREN'S HOSPITAL	SITZMAN-20-04		-\$4,896	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	SITZMAN-20-04	PHOENIX CHILDREN'S HOSPITAL	SITZMAN-20-04		\$51,017	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	SITZMAN-20-04	PHOENIX CHILDREN'S HOSPITAL	SITZMAN-20-04		\$48,443	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	311003	CHILDREN'S HOSPITAL MEDICAL CENTER	311003		\$16,941	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	311003	CHILDREN'S HOSPITAL MEDICAL CENTER	311003		\$74	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	ULRF_21-0285-01	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.	ULRF_21-0285-01		\$34,021	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	ULRF_21-0285-01	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.	ULRF_21-0285-01		\$51,249	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	12736SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12736SUB		\$8,165	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL DISEASES AND DISORDERS RESEARCH	93.121	12736SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12736SUB		\$20,990	\$1,896,259	RESEARCH AND DEVELOPMENT	\$82,409,498
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	EIIC	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	EIIC		\$59,405	\$825,081	RESEARCH AND DEVELOPMENT	\$82,409,498
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	EIIC	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	EIIC		\$37,835	\$825,081	RESEARCH AND DEVELOPMENT	\$82,409,498
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 U03MC28844-06-00				-\$61	\$825,081	RESEARCH AND DEVELOPMENT	\$82,409,498
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 U03MC28844-07-00			\$331,231	\$571,933	\$825,081	RESEARCH AND DEVELOPMENT	\$82,409,498
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 U03MC28844-08-00				\$155,969	\$825,081	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00			\$13,583	\$138,988	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$81,207	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00			\$40,994	\$91,410	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$2,930	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00			\$18,295	\$46,135	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$48,698	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00			\$15,000	\$104,927	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$95,707	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-04-00				\$55,458	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-04-00				\$1,030	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-04-00				\$14,617	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-04-00				\$7,670	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-04-00				\$56,321	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-04-00				\$58,054	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R01CE003349-01-00			\$39,486	\$368,332	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R01CE003349-02-00				\$103,228	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	RESS14916	CASE WESTERN RESERVE UNIVERSITY	RESS14916		\$28,189	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	RESS14916	CASE WESTERN RESERVE UNIVERSITY	RESS14916		\$11,043	\$1,313,944	RESEARCH AND DEVELOPMENT	\$82,409,498
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	FCPH - COVID HEALTH LITERACY	FRANKLIN COUNTY BOARD OF PUBLIC HEALTH	FCPH - COVID HEALTH LITERACY		\$320,988	\$1,034,041	N/A	\$0

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	FCPH - COVID HEALTH LITERACY	FRANKLIN COUNTY BOARD OF PUBLIC HEALTH	FCPH - COVID HEALTH LITERACY		\$255,268	\$1,034,041	N/A	\$0
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	1 CPIMP201202-01-00			\$40,271	\$53,004	\$1,034,041	RESEARCH AND DEVELOPMENT	\$82,409,498
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	5 CPIMP201202-02-00			\$45,000	\$350,848	\$1,034,041	RESEARCH AND DEVELOPMENT	\$82,409,498
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	5 CPIMP201202-03-00				\$53,933	\$1,034,041	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	U41HG007635				\$1,619	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	5K01HG011062-02				\$45,666	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	5K01HG011062-03				\$79,730	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	4R00HG010157-04				\$115,411	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	5R00HG010157-05				\$347,692	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	1R35HG011949-01				\$317,961	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	5R35HG011949-02				\$166,958	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	025040A	IOWA STATE UNIVERSITY	025040A		\$143,136	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
HUMAN GENOME RESEARCH	93.172	025040A	IOWA STATE UNIVERSITY	025040A		\$162,626	\$1,380,799	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-10				\$243,133	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-10				\$151,114	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2R01DC003915-21A1				\$73,818	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2R01DC003915-21A1				\$34,233	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2R01DC003915-21A1				\$17,480	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC003915-22				\$265,984	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC003915-22				\$110,498	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC003915-22				\$96,929	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC015688-05			\$11,024	\$16,564	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60057049-NCH	THE OHIO STATE UNIVERSITY	60057049-NCH		\$9,739	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	GR114168 SPC-1000004882	THE OHIO STATE UNIVERSITY	GR114168 SPC-1000004882		\$43,030	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	SPC-1000003922 GR116989	THE OHIO STATE UNIVERSITY	SPC-1000003922 GR116989		\$39,184	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	GR116989	THE OHIO STATE UNIVERSITY	GR116989		\$13,701	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60072793	THE OHIO STATE UNIVERSITY	60072793		-\$4,058	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	10041913-039	THE UNIVERSITY OF UTAH	10041913-039		\$870	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	GR118125 / SPC-1000005060	THE OHIO STATE UNIVERSITY	GR118125 / SPC-1000005060		\$47,661	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	GR118125 / SPC-1000005060	THE OHIO STATE UNIVERSITY	GR118125 / SPC-1000005060		\$100,889	\$1,260,769	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	4R33AT009632-03				\$713	\$658,456	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5R33AT009632-04				\$263,356	\$658,456	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5R33AT009632-05				\$147,528	\$658,456	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1R34AT011218-01A1			\$57,224	\$161,140	\$658,456	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5R34AT011218-02				\$85,719	\$658,456	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1R01HS029183-01				\$33,248	\$201,213	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1R01HS028413-01A1			\$7,945	\$120,298	\$201,213	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	FY20.861.001	UNIVERSITY OF COLORADO DENVER	FY20.861.001		\$7,525	\$201,213	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	FY20.861.001	UNIVERSITY OF COLORADO DENVER	FY20.861.001		\$6,590	\$201,213	RESEARCH AND DEVELOPMENT	\$82,409,498
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	SUBK00014367	REGENTS UNIVERSITY OF MICHIGAN	SUBK00014367		\$33,552	\$201,213	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	3210920620	CHILDREN'S HOSPITAL OF PHILADELPHIA	3210920620		\$34,764	\$34,764	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH117594-04			\$58,675	\$232,090	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1R01MH123746-01A1			\$268,923	\$475,608	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH123746-02			\$77,027	\$239,451	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1R01MH125905-01A1				\$18,926	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1K01MH127417-01A1				\$59,962	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	1P50MH127476-01A1				\$141,210	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1P50MH127476-01A1				\$281,762	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1P50MH127476-01A1				\$10,319	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1P50MH127476-01A1				\$185,543	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	568947	UNIVERSITY OF PENNSYLVANIA	568947		\$843	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	1855	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	1855		\$68,851	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	2268	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	2268		\$62,895	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	12683SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12683SUB		\$165,412	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	12683SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12683SUB		\$195,953	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
MENTAL HEALTH RESEARCH GRANTS	93.242	GR127541 SPC-1000007274	THE OHIO STATE UNIVERSITY	GR127541 SPC-1000007274		\$32,365	\$2,171,190	RESEARCH AND DEVELOPMENT	\$82,409,498
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	1H79SM084968-01			\$51,840	\$283,169	\$346,387	RESEARCH AND DEVELOPMENT	\$82,409,498
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	5H79SM084968-02				\$63,218	\$346,387	RESEARCH AND DEVELOPMENT	\$82,409,498
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4BH515471-13-00				\$269,714	\$386,927	N/A	\$0
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4BH515471-13-00				\$117,213	\$386,927	N/A	\$0
ALCOHOL RESEARCH PROGRAMS	93.273	1R01AA027502-01A1				-\$775	\$374,257	RESEARCH AND DEVELOPMENT	\$82,409,498
ALCOHOL RESEARCH PROGRAMS	93.273	5R01AA027502-02				\$66,729	\$374,257	RESEARCH AND DEVELOPMENT	\$82,409,498
ALCOHOL RESEARCH PROGRAMS	93.273	5R01AA027502-03				\$276,829	\$374,257	RESEARCH AND DEVELOPMENT	\$82,409,498
ALCOHOL RESEARCH PROGRAMS	93.273	GR122831	THE OHIO STATE UNIVERSITY	GR122831		\$4,392	\$374,257	RESEARCH AND DEVELOPMENT	\$82,409,498
ALCOHOL RESEARCH PROGRAMS	93.273	GR122831 SPC-1000004910	THE OHIO STATE UNIVERSITY	GR122831 SPC-1000004910		\$27,082	\$374,257	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R01DA042948-03				\$10,693	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R01DA052580-01A1				\$153,362	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R01DA052580-02				\$307,291	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	SPC-1000005500	THE OHIO STATE UNIVERSITY	SPC-1000005500		\$8,462	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	SPC-1000006472 GR126019	THE OHIO STATE UNIVERSITY	SPC-1000006472 GR126019		\$11,477	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	GR122007	THE OHIO STATE UNIVERSITY	GR122007		\$132,793	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	GR122007 / SPC-1000004551	THE OHIO STATE UNIVERSITY	GR122007 / SPC-1000004551		\$290,022	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	GR122009 / SPC-1000004557	THE OHIO STATE UNIVERSITY	GR122009 / SPC-1000004557		\$91,052	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1009-55811085045103-1100000018	WAKE FOREST UNIVERSITY HEALTH SCIENCES	1009-55811085045103-1100000018		\$30,386	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1009-45103-11000000186	WAKE FOREST UNIVERSITY HEALTH SCIENCES	1009-45103-11000000186		\$14,135	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	RNG003002-NCH	KAISER PERMANENTE	RNG003002-NCH		\$1,286	\$1,050,959	RESEARCH AND DEVELOPMENT	\$82,409,498
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R21EB026518-03				\$48,897	\$116,945	RESEARCH AND DEVELOPMENT	\$82,409,498
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R21EB026518-03S1			\$813	\$813	\$116,945	RESEARCH AND DEVELOPMENT	\$82,409,498
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	GR123843 / SPC-1000005624	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	GR123843 / SPC-1000005624		\$38,342	\$116,945	RESEARCH AND DEVELOPMENT	\$82,409,498
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	GR123843 / SPC-1000005624	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	GR123843 / SPC-1000005624		\$28,893	\$116,945	RESEARCH AND DEVELOPMENT	\$82,409,498
TEENAGE PREGNANCY PREVENTION PROGRAM	93.297	5 TP1AH000212-02-00			\$173,348	\$697,212	\$1,143,641	RESEARCH AND DEVELOPMENT	\$82,409,498
TEENAGE PREGNANCY PREVENTION PROGRAM	93.297	5 TP1AH000212-03-00			\$64,686	\$446,429	\$1,143,641	RESEARCH AND DEVELOPMENT	\$82,409,498
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R01MD013881-03				\$110,150	\$570,784	RESEARCH AND DEVELOPMENT	\$82,409,498
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1R21MD015860-01			\$11,605	\$17,873	\$570,784	RESEARCH AND DEVELOPMENT	\$82,409,498
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R21MD015860-02			\$27,730	\$175,154	\$570,784	RESEARCH AND DEVELOPMENT	\$82,409,498
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1R01MD016064-01A1				\$262,010	\$570,784	RESEARCH AND DEVELOPMENT	\$82,409,498
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	RF00235-2021-0350	UNIV OF TX HEALTH SCIENCE CTR	RF00235-2021-0350		\$5,597	\$570,784	RESEARCH AND DEVELOPMENT	\$82,409,498
TRANS-NIH RESEARCH SUPPORT	93.310	3R35HG011949-02S1				\$68,609	\$114,814	RESEARCH AND DEVELOPMENT	\$82,409,498
TRANS-NIH RESEARCH SUPPORT	93.310	19-A0-00-1003237	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	19-A0-00-1003237		\$8,524	\$114,814	RESEARCH AND DEVELOPMENT	\$82,409,498
TRANS-NIH RESEARCH SUPPORT	93.310	19-A0-00-1003237	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	19-A0-00-1003237		\$4,190	\$114,814	RESEARCH AND DEVELOPMENT	\$82,409,498
TRANS-NIH RESEARCH SUPPORT	93.310	3RGH1	THE REGENTS OF THE UNIVERSITY OF NEW MEXICO	3RGH1		\$15,224	\$114,814	RESEARCH AND DEVELOPMENT	\$82,409,498
TRANS-NIH RESEARCH SUPPORT	93.310	3RGH1	THE REGENTS OF THE UNIVERSITY OF NEW MEXICO	3RGH1		\$2,104	\$114,814	RESEARCH AND DEVELOPMENT	\$82,409,498
TRANS-NIH RESEARCH SUPPORT	93.310	SPC-1000006687 GR123331	THE OHIO STATE UNIVERSITY	SPC-1000006687 GR123331		\$16,163	\$114,814	RESEARCH AND DEVELOPMENT	\$82,409,498



**NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)**

**Fiscal Period 1/1/2022 - 12/31/2022**

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIETARY SUPPLEMENT RESEARCH PROGRAM	93.321	1R01HD102439-01A1			\$20,335	\$212,762	\$486,542	RESEARCH AND DEVELOPMENT	\$82,409,498
DIETARY SUPPLEMENT RESEARCH PROGRAM	93.321	5R01HD102439-02				\$273,780	\$486,542	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000006088 GR123361	THE OHIO STATE UNIVERSITY	SPC-1000006088 GR123361		\$64,615	\$745,086	N/A	\$0
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000006088 GR123361	THE OHIO STATE UNIVERSITY	SPC-1000006088 GR123361		\$25,852	\$745,086	N/A	\$0
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738		\$5,045	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322		\$227,790	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322		\$10,967	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322		\$1,338	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322		\$6,682	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322		\$75,736	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000006837/GR127008	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000006837/GR127008		\$309,890	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000006837/GR127008	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000006837/GR127008		\$502	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	203-7853	DUKE UNIVERSITY	203-7853		\$342	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	A031871 / SITE NWC99	DUKE UNIVERSITY	A031871 / SITE NWC99		\$2,270	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	FP00010833_SA002	VIRGINIA COMMONWEALTH UNIVERSITY	FP00010833_SA002		\$2,095	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	FP00010833_SA002	VIRGINIA COMMONWEALTH UNIVERSITY	FP00010833_SA002		\$11,962	\$745,086	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U01CA232488-01			\$118,377	\$474,267	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA231641-01			\$695,832	\$1,547,597	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$169,356	\$256,808	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$162,885	\$420,087	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$78,345	\$322,418	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1				\$205,732	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$49,970	\$363,273	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	3U54CA232561-01A1S3			\$20,947	\$91,651	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	3U54CA232561-01A1S4				\$48,898	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	3201380822-52	CHILDREN'S HOSPITAL OF PHILADELPHIA	3201380822-52		\$58,506	\$3,789,237	RESEARCH AND DEVELOPMENT	\$82,409,498
PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE	93.354	49670-11/VDR OAKS 000005476-03	OHIO DEPARTMENT OF HEALTH	49670-11/VDR OAKS 000005476-03		\$166,096	\$318,261	N/A	\$0
PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE	93.354	CSP008823 SRC0000002665	OHIO DEPARTMENT OF HEALTH	CSP008823 SRC0000002665		\$152,165	\$318,261	N/A	\$0
NURSING RESEARCH	93.361	FY22.1180.001	UNIVERSITY OF COLORADO DENVER	FY22.1180.001		\$62,870	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	5R01NR017533-04			\$78,586	\$137,482	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	5R01NR017533-05				\$288,857	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	4R00NR019115-03				\$174,303	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	1K99NR019115-01A1				\$0	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	5K99NR019115-02				\$35,542	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	1R01NR020423-01A1				\$57,902	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	1300205	DANA FARBER CANCER INSTITUTE	1300205		\$2,052	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	304482	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	304482		\$33,742	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	304482	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	304482		\$41,600	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	204-55811085045116-10000550114	WAKE FOREST UNIVERSITY HEALTH SCIENCES	204-55811085045116-10000550114		\$60,776	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
NURSING RESEARCH	93.361	204-45116-10000550114	WAKE FOREST UNIVERSITY HEALTH SCIENCES	204-45116-10000550114		\$42,117	\$937,243	RESEARCH AND DEVELOPMENT	\$82,409,498
INTEGRATED CARE FOR KIDS MODEL	93.378	282CMS331798-02-00	CENTERS FOR MEDICARE & MEDICAID SERVICES	282CMS331798-02-00	\$20,118	\$126,883	\$2,316,134	RESEARCH AND DEVELOPMENT	\$82,409,498
INTEGRATED CARE FOR KIDS MODEL	93.378	282CMS331798-03-00	CENTERS FOR MEDICARE & MEDICAID SERVICES	282CMS331798-03-00	\$280,263	\$2,189,251	\$2,316,134	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ACTIVITIES TO SUPPORT STATE, TRIBAL, LOCAL AND TERRITORIAL (SLT) HEALTH DEPARTMENT RESPONSE TO PUBLIC HEALTH OR HEALTHCARE CRISES	93.391	025605110I0123	OHIO DEPARTMENT OF HEALTH	025605110I0123		\$26,626	\$26,626	N/A	\$0
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R21CA227926-02				-\$23,945	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA248103-01A1			\$88,669	\$140,381	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R01CA248103-01A152				\$7,152	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R01CA248103-01A151				\$7,092	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA248103-02			\$106,964	\$244,996	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R01CA248103-0252				\$60,848	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R01CA248103-0251				\$61,918	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA272872-01				\$25,125	\$523,567	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-05				-\$7	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-05				-\$1	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA239754-03				\$125,834	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA239754-04				\$579,096	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$36,141	\$627,277	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07				\$4,763	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07				\$979	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07				\$74,819	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07				\$970	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$192	\$327,272	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$384	\$20,949	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07				\$713	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07				\$150,951	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08			\$35,293	\$2,617,193	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$4,220	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$12,290	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$2,213	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$864	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$168,060	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$44,429	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$1,319,567	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08S1				\$232	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-08				\$3,436	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA254445-02				\$1,246,891	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA254445-03				\$1,510,152	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-07			\$159,704	\$890,370	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-07				\$112,903	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-08			\$133,683	\$2,034,413	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-08				\$257,311	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205604	DANA FARBER CANCER INSTITUTE	1205604		\$29,312	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205604	DANA FARBER CANCER INSTITUTE	1205604		\$217,516	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	GR111019	MEDICAL CENTER	GR111019		\$53,951	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ		\$477,761	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ		\$52,347	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ		\$1,210,085	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ		\$144,216	\$14,323,347	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	5R21CA223104-02				-\$148	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	111287270-7969226	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287270-7969226		\$665	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	60059472	THE OHIO STATE UNIVERSITY	60059472		-\$1,103	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	000518779-SC001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518779-SC001		\$9,576	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR03996	PUBLIC HEALTH INSTITUTE	AR03996		\$12,541	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR13809	PUBLIC HEALTH INSTITUTE	AR13809		\$76,678	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR03219	PUBLIC HEALTH INSTITUTE	AR03219		\$2,029	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR10932	PUBLIC HEALTH INSTITUTE	AR10932		\$7,718	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	1013080-004_NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-004_NATIONWIDE		\$382	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	1013080-004_NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-004_NATIONWIDE		\$65	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR03755	PUBLIC HEALTH INSTITUTE	AR03755		\$2,369	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR03755	PUBLIC HEALTH INSTITUTE	AR03755		\$0	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR03293	PUBLIC HEALTH INSTITUTE	AR03293		\$805	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	60070505-NCH	THE OHIO STATE UNIVERSITY	60070505-NCH		\$3,045	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR03745	PUBLIC HEALTH INSTITUTE	AR03745	\$29,852	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR14099	PUBLIC HEALTH INSTITUTE	AR14099	\$168,162	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	ACNS1422 / 20126538 - RSUB	PUBLIC HEALTH INSTITUTE	ACNS1422 / 20126538 - RSUB	\$0	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03752	PUBLIC HEALTH INSTITUTE	AR03752	\$10,379	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR59586	PUBLIC HEALTH INSTITUTE	AR59586	\$98,857	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	FP00029870_SUB01_02	PUBLIC HEALTH INSTITUTE	FP00029870_SUB01_02	\$0	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03764	PUBLIC HEALTH INSTITUTE	AR03764	\$43,077	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR59587	PUBLIC HEALTH INSTITUTE	AR59587	\$204,340	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03769	PUBLIC HEALTH INSTITUTE	AR03769	\$9,401	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR59581	PUBLIC HEALTH INSTITUTE	AR59581	\$14,342	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03765	PUBLIC HEALTH INSTITUTE	AR03765	\$18,053	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03765	PUBLIC HEALTH INSTITUTE	AR03765	\$39,566	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR04539	PUBLIC HEALTH INSTITUTE	AR04539	\$555	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB267_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00026529_SUB267_01	-\$88,286	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03746	PUBLIC HEALTH INSTITUTE	AR03746	-\$3,963	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR14100	PUBLIC HEALTH INSTITUTE	AR14100	\$9,544	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03750	PUBLIC HEALTH INSTITUTE	AR03750	\$7,603	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	FP00026537_SUB13_03	THE CHILDREN'S HOSPITAL OF PA	FP00026537_SUB13_03	\$1,385	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03759 AR04918	PUBLIC HEALTH INSTITUTE	AR03759 AR04918	\$5,679	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR14111	PUBLIC HEALTH INSTITUTE	AR14111	\$21,535	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	S01426-01	THE UNIVERSITY OF IOWA	S01426-01	\$10,465	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	S01426-01	THE UNIVERSITY OF IOWA	S01426-01	\$6,731	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	GY012-RAMIREZ-GY7	NRG ONCOLOGY FOUNDATION	GY012-RAMIREZ-GY7	-\$229	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	SARCO37-5	SARCOMA ALLIANCE FOR RESEARCH THROUGH	SARCO37-5	\$19,978	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	111287261-7951318	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287261-7951318	-\$939	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	11128728P-8090145	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	11128728P-8090145	\$69,053	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	110068220-7997444	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	110068220-7997444	\$11,946	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	110068220-7997444	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	110068220-7997444	\$52,805	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	110068210-7957794	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	110068210-7957794	\$7,863	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	110068210-7957794	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	110068210-7957794	\$3,650	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	GRT-00000636	THE CHILDREN'S HOSPITAL OF PA	GRT-00000636	-\$7	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	GRT-00000636	THE CHILDREN'S HOSPITAL OF PA	GRT-00000636	\$14,106	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	1013080-014_ NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-014_ NATIONWIDE	\$2,077	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	1013080-014_ NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-014_ NATIONWIDE	\$78,474	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	ACCL1633 GRT-00000608	CHILDREN'S HOSPITAL OF PHILADELPHIA	ACCL1633 GRT-00000608	\$1,159	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR06695	PUBLIC HEALTH INSTITUTE	AR06695	\$7,036	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR06695	PUBLIC HEALTH INSTITUTE	AR06695	\$4,554	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR06698	PUBLIC HEALTH INSTITUTE	AR06698	\$8,536	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR59590	PUBLIC HEALTH INSTITUTE	AR59590	\$32,736	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03768	PUBLIC HEALTH INSTITUTE	AR03768	\$14,122	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR14106	PUBLIC HEALTH INSTITUTE	AR14106	\$21,084	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03762	PUBLIC HEALTH INSTITUTE	AR03762	\$5,298	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR14113	PUBLIC HEALTH INSTITUTE	AR14113	\$13,592	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03269	PUBLIC HEALTH INSTITUTE	AR03269	\$27,473	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR11015	PUBLIC HEALTH INSTITUTE	AR11015	\$49,845	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR03418	PUBLIC HEALTH INSTITUTE	AR03418	\$12,889	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	AR13064	PUBLIC HEALTH INSTITUTE	AR13064	\$19,570	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	FP00021956_A1_SUB64_0,1	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00021956_A1_SUB64_0,1	\$1,508	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	SUB TO U10CA180886	PUBLIC HEALTH INSTITUTE	SUB TO U10CA180886	\$22,843	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	
CANCER TREATMENT RESEARCH	93.395	11128728H-8084359	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	11128728H-8084359	\$29,003	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498	

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	11128728H-8084359	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	11128728H-8084359		\$1,821	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR04567	PUBLIC HEALTH INSTITUTE	AR04567		\$4,558	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	U10CA180886 W/L	PUBLIC HEALTH INSTITUTE	U10CA180886 W/L		\$36,920	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR05288 / PO0000003338	PUBLIC HEALTH INSTITUTE	AR05288 / PO0000003338		\$8,278	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR05288 / PO0000003338	PUBLIC HEALTH INSTITUTE	AR05288 / PO0000003338		\$18,596	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER TREATMENT RESEARCH	93.395	AR59604	PUBLIC HEALTH INSTITUTE	AR59604		\$6,954	\$1,329,051	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	1R03CA259865-01				-\$589	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	1R03CA259865-01			\$3,787	\$3,787	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	5R03CA259865-02				\$42,469	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	1R01CA247941-01A1			\$26,104	\$58,101	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	5R01CA247941-02			\$23,959	\$363,318	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	1R01CA262873-01				\$364,636	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	5R01CA262873-02				\$92,978	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	3R01CA262873-02S1				\$4,360	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	1R01CA260178-01A1				\$127,655	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	SUP1601	CHILDREN'S HOSPITAL OF LOS ANGELES	SUP1601		-\$859	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	10037968-NCH	THE UNIVERSITY OF UTAH	10037968-NCH		\$4,502	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	A00-4018-S001	MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-4018-S001		-\$45	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	A00-4018-S001	MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-4018-S001		\$25,233	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	GR124958	THE OHIO STATE UNIVERSITY	GR124958		\$16,646	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER BIOLOGY RESEARCH	93.396	GR124958	THE OHIO STATE UNIVERSITY	GR124958		\$4,268	\$1,106,460	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CENTERS SUPPORT GRANTS	93.397	3U54CA232561-01A1S5				\$4,397	\$102,369	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CENTERS SUPPORT GRANTS	93.397	S02159-01	THE UNIVERSITY OF IOWA	S02159-01		\$24,324	\$102,369	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CENTERS SUPPORT GRANTS	93.397	SPC-1000005696 / GR121877	THE OHIO STATE UNIVERSITY	SPC-1000005696 / GR121877		\$17,522	\$102,369	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CENTERS SUPPORT GRANTS	93.397	SPC-1000005696 / GR121877	THE OHIO STATE UNIVERSITY	SPC-1000005696 / GR121877		\$4,633	\$102,369	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CENTERS SUPPORT GRANTS	93.397	SPC-1000005009 / GR121872	THE OHIO STATE UNIVERSITY	SPC-1000005009 / GR121872		\$19,045	\$102,369	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CENTERS SUPPORT GRANTS	93.397	SPC-1000005010 / GR121873	THE OHIO STATE UNIVERSITY	SPC-1000005010 / GR121873		\$32,448	\$102,369	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER RESEARCH MANPOWER	93.398	5K08CA201638-05				-\$317	\$326,209	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER RESEARCH MANPOWER	93.398	5K08CA237338-03				\$42,845	\$326,209	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER RESEARCH MANPOWER	93.398	5K08CA237338-04				\$142,224	\$326,209	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER RESEARCH MANPOWER	93.398	1T32CA269052-01				\$79,722	\$326,209	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER RESEARCH MANPOWER	93.398	GR124657 SPC-1000005411	OHIO STATE UNIVERSITY ILAB	GR124657 SPC-1000005411		\$40,786	\$326,209	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER RESEARCH MANPOWER	93.398	GR124657 SPC-1000005411	OHIO STATE UNIVERSITY ILAB	GR124657 SPC-1000005411		\$20,949	\$326,209	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CONTROL	93.399	FORTE-RAMIREZ-GY8	NRG ONCOLOGY FOUNDATION	FORTE-RAMIREZ-GY8		\$9,184	\$25,686	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CONTROL	93.399	FORTE-RAMIREZ-GY8	NRG ONCOLOGY FOUNDATION	FORTE-RAMIREZ-GY8		\$14,104	\$25,686	RESEARCH AND DEVELOPMENT	\$82,409,498
CANCER CONTROL	93.399	7UG1CA189955-08	PUBLIC HEALTH INSTITUTE	7UG1CA189955-08		\$2,398	\$25,686	RESEARCH AND DEVELOPMENT	\$82,409,498
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	PI-CD33-PCOR	TASK FORCE GLOBAL HEALTH INC	PI-CD33-PCOR		\$21,958	\$183,430	RESEARCH AND DEVELOPMENT	\$82,409,498
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	PI-CD33-PCOR	TASK FORCE GLOBAL HEALTH INC	PI-CD33-PCOR		\$18,869	\$183,430	RESEARCH AND DEVELOPMENT	\$82,409,498
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	GR124559	THE OHIO STATE UNIVERSITY	GR124559		\$112,001	\$183,430	RESEARCH AND DEVELOPMENT	\$82,409,498
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	GR129392	THE OHIO STATE UNIVERSITY	GR129392		\$30,602	\$183,430	RESEARCH AND DEVELOPMENT	\$82,409,498
NON-ACA/PPHF BUILDING CAPACITY OF THE PUBLIC HEALTH SYSTEM TO IMPROVE POPULATION HEALTH THROUGH NATIONAL NONPROFIT ORGANIZATIONS	93.424	CDC7073-0-0183-1	CHANGELAB SOLUTIONS	CDC7073-0-0183-1		\$3,728	\$3,728	RESEARCH AND DEVELOPMENT	\$82,409,498
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	315804	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	315804		\$3,501	\$11,238	RESEARCH AND DEVELOPMENT	\$82,409,498
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	315804	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	315804		\$7,737	\$11,238	RESEARCH AND DEVELOPMENT	\$82,409,498

## NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

## SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
COMMUNITY HEALTH WORKERS FOR PUBLIC HEALTH RESPONSE AND RESILIENT	93.495	CDCCCR	HEALTHCARE COLLABORATIVE OF GREATER COLUMBUS	CDCCCR		\$38,031	\$56,490	RESEARCH AND DEVELOPMENT	\$82,409,498
COMMUNITY HEALTH WORKERS FOR PUBLIC HEALTH RESPONSE AND RESILIENT	93.495	CDCCCR	HEALTHCARE COLLABORATIVE OF GREATER COLUMBUS	CDCCCR		\$18,459	\$56,490	RESEARCH AND DEVELOPMENT	\$82,409,498
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	G-2021-22-0228-01	OHIO CHILDRENS TRUST FUND	G-2021-22-0228-01	\$2,337	\$2,337	\$33,439	N/A	\$0
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	25-23-3659	FRANKLIN COUNTY DEPARTMENT OF JOB AND FAMILY SERVICES	25-23-3659		\$5,338	\$33,439	N/A	\$0
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	25-21-3536	FRANKLIN COUNTY DEPARTMENT OF JOB AND FAMILY SERVICES	25-21-3536		\$25,764	\$33,439	N/A	\$0
CHILD CARE AND DEVELOPMENT BLOCK GRANT	93.575	OHIO CHILDREN'S ALLIANCE	OHIO CHILDREN'S ALLIANCE	OHIO CHILDREN'S ALLIANCE		\$98,543	\$232,932	CCDF CLUSTER	\$798,116
CHILD CARE AND DEVELOPMENT BLOCK GRANT	93.575	OHIO CHILDREN'S ALLIANCE	OHIO CHILDREN'S ALLIANCE	OHIO CHILDREN'S ALLIANCE		\$131,020	\$232,932	CCDF CLUSTER	\$798,116
CHILD CARE AND DEVELOPMENT BLOCK GRANT	93.575	IECMH	OHIO CHILDREN'S ALLIANCE	IECMH		\$3,369	\$232,932	CCDF CLUSTER	\$798,116
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0848	OHIO CHILDRENS TRUST FUND	G-2223-22-0848		\$19,897	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0848	OHIO CHILDRENS TRUST FUND	G-2223-22-0848		\$1,980	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246	OHIO CHILDRENS TRUST FUND	G-2223-22-0246		\$42,153	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246	OHIO CHILDRENS TRUST FUND	G-2223-22-0246	\$294,190	\$524,872	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246	OHIO CHILDRENS TRUST FUND	G-2223-22-0246	\$73,710	\$73,710	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246	OHIO CHILDRENS TRUST FUND	G-2223-22-0246	\$23,191	\$25,066	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246-1	OHIO CHILDRENS TRUST FUND	G-2223-22-0246-1		\$52,052	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246-1	OHIO CHILDRENS TRUST FUND	G-2223-22-0246-1		\$37,873	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246-1	OHIO CHILDRENS TRUST FUND	G-2223-22-0246-1		\$10,474	\$797,381	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246-1	OHIO CHILDRENS TRUST FUND	G-2223-22-0246-1		\$9,304	\$797,381	N/A	\$0
CHILD CARE MANDATORY AND MATCHING FUNDS OF THE CHILD CARE AND DEVELOPMENT FUND	93.596	COVID-19	OHIO CHILD CARE RESOURCE AND REFERRAL ASSOCIATION	COVID-19		\$565,184	\$565,184	CCDF CLUSTER	\$798,116
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	GR125049	THE OHIO STATE UNIVERSITY	GR125049		\$22,326	\$28,666	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	GR128419	THE OHIO STATE UNIVERSITY	GR128419		\$6,340	\$28,666	N/A	\$0
MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732	1 U3NHP45413-01-00			\$51,619	\$485,353	\$485,353	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$45,708	\$253,761	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$102,924	\$253,761	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$22,195	\$253,761	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$17,842	\$253,761	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$43,246	\$253,761	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$21,846	\$253,761	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837	1K23HL159312-01A1				\$83,820	\$3,928,481	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837	SUBK00017404	UNIVERSITY OF MICHIGAN	SUBK00017404		\$49	\$3,928,481	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K23HL127224-05				\$5,906	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135657-04				\$109,927	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL139796-04			\$22,257	\$58,191	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-02				-\$387	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-03			\$50,115	\$72,923	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-04			\$52,370	\$417,591	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-05				\$13,597	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135103-05			\$10,926	\$352,655	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R03HL148368-02				\$7,850	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL144009-02				\$64	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL144009-03				\$206,792	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL144009-04				\$129,215	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL146582-02				\$127,484	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL146582-03				\$361,896	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL155282-01				\$31,101	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL155282-02				\$273,458	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3R01HL155282-02S1				\$51,491	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	4UH3HL148693-02				\$32,582	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5UH3HL148693-03				\$278,591	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3UH3HL148693-03S1				\$351	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL157491-01			\$19,123	\$184,218	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL157491-02			\$3,699	\$395,346	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3R01HL157491-02S1				\$5,541	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3R01HL157491-02S2				\$5,883	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R21HL161823-01				\$109,963	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	1UG3HL161338-01			\$16,904	\$148,584	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	2R01HL139796-05				\$82,014	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R21HL165406-01				\$24,309	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498

## NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

## SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1223992	UNIVERSITY AT BUFFALO	R1223992		\$106,025	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3200170321	CHILDREN'S HOSPITAL OF PHILADELPHIA	3200170321		\$40,044	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	GR119792	THE OHIO STATE UNIVERSITY	GR119792		\$310	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3004465579	REGENTS UNIVERSITY OF MICHIGAN	3004465579		-\$3,010	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	FUEL-OLE	NEW ENGLAND RESEARCH CENTER	FUEL-OLE		\$2,182	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000000719	BAYLOR COLLEGE OF MEDICINE	7000000719		\$13,357	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000000719	BAYLOR COLLEGE OF MEDICINE	7000000719		\$17,907	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	3201630222	CHILDREN'S HOSPITAL OF PHILADELPHIA	3201630222		\$4,247	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1227445	UNIVERSITY AT BUFFALO	R1227445		\$37,157	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1227445	UNIVERSITY AT BUFFALO	R1227445		\$88,827	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R43HL152844-01	LYST THERAPEUTICS, LLC	1R43HL152844-01		\$26,047	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	RESS15518	CASE WESTERN RESERVE UNIVERSITY	RESS15518		\$3,657	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	RESS15518	CASE WESTERN RESERVE UNIVERSITY	RESS15518		\$10,618	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000001321	BAYLOR COLLEGE OF MEDICINE	7000001321		\$10,108	\$3,928,481	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	1F32HL154602-01A1				\$46,678	\$2,543,241	N/A	\$0
LUNG DISEASES RESEARCH	93.838	10059528-01-NWC	THE UNIVERSITY OF UTAH	10059528-01-NWC		\$23,533	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5K08HL129080-05				\$18,264	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5K08HL138460-05				\$64,135	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL136963-03				-\$157	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL136963-04			\$11,549	\$17,076	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL136963-05				\$267,714	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL148171-02			\$2,169	\$100,691	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL148171-03			\$1,520	\$154,669	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	1R01HL155095-01				\$101	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL155095-02				\$404,303	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL155095-03				\$13,546	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	1R01HL157039-01			\$58,211	\$284,565	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL157039-02			\$39,365	\$270,139	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	1R01HL158747-01A1			\$22,949	\$72,608	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	1R01HL158747-01A1				\$86,509	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	4R00HL151900-03				\$25,497	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	GR110932	THE OHIO STATE UNIVERSITY	GR110932		\$0	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	GR110932	THE OHIO STATE UNIVERSITY	GR110932		\$31,096	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	GR110932 / SPC-1000003691	THE OHIO STATE UNIVERSITY	GR110932 / SPC-1000003691		\$32,801	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	SUBK00014476	REGENTS UNIVERSITY OF MICHIGAN	SUBK00014476		\$2,269	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	A033918 (SPS-258271)	DUKE UNIVERSITY	A033918 (SPS-258271)		\$4,277	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	0008871/02262021	UNIVERSITY OF RHODE ISLAND	0008871/02262021		-\$12,787	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	0008871/02262021	UNIVERSITY OF RHODE ISLAND	0008871/02262021		\$135,982	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	0008871/02262021	UNIVERSITY OF RHODE ISLAND	0008871/02262021		\$97,774	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	WSU22076	WAYNE STATE UNIVERSITY	WSU22076		\$9,586	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	WSU22076	WAYNE STATE UNIVERSITY	WSU22076		\$3,064	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	WSU22142	WAYNE STATE UNIVERSITY	WSU22142		\$13,015	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	WSU22142	WAYNE STATE UNIVERSITY	WSU22142		\$11,154	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	GRT-00001622	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00001622		\$274,891	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	RES-299544; PO# 68815828	MAYO CLINIC	RES-299544; PO# 68815828		\$23,403	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	1R01HL158747-01A1	EMORY UNIVERSITY	1R01HL158747-01A1		\$55,627	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
LUNG DISEASES RESEARCH	93.838	5R01HL148171-03	EMORY UNIVERSITY	5R01HL148171-03		\$11,218	\$2,543,241	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R03HL146877-02				\$3,160	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R21HL150487-02			\$1,095	\$30,185	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R01HL157208-01A1			\$13,801	\$250,732	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R01HL160935-01A1				\$106,283	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	ACRI 19-001	ALL CHILDREN'S RESEARCH INSTITUTE, INC.	ACRI 19-001		-\$18	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	PBMTC STUDY NO. 1507	CHILDREN'S HOSPITAL OF LOS ANGELES	PBMTC STUDY NO. 1507		\$5,037	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1U01HL143477	THE MEDICAL COLLEGE OF WISCONSIN	1U01HL143477		-\$8	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	3201710624	THE CHILDREN'S HOSPITAL OF PA	3201710624		\$114	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	3201710624	THE CHILDREN'S HOSPITAL OF PA	3201710624		\$3,922	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A412639	EMORY UNIVERSITY	A412639		-\$25	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A412639	EMORY UNIVERSITY	A412639		-\$35,283	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1001432-01-NCH	VERSITI BLOOD CENTER OF WISCONSIN	1001432-01-NCH		\$48,698	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1001432-NCH	VERSITI BLOOD CENTER OF WISCONSIN	1001432-NCH		\$44,555	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	6207923	THE MEDICAL COLLEGE OF WISCONSIN, INC.	6207923		\$19,591	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	6207923	THE MEDICAL COLLEGE OF WISCONSIN, INC.	6207923		\$17,831	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A570986	EMORY UNIVERSITY	A570986		\$87,633	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A570986	EMORY UNIVERSITY	A570986		\$3,236	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A570986	EMORY UNIVERSITY	A570986		\$9,024	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A570986	EMORY UNIVERSITY	A570986		\$23,756	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	GMO 210710	UT SOUTHWESTERN MEDICAL CENTER	GMO 210710		\$1,076	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN PROTOCOL #1904	NATIONAL MARROW DONOR PROGRAM	BMT CTN PROTOCOL #1904		\$3,650	\$623,149	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	GRANT ID: GRT-00001510	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRANT ID: GRT-00001510		\$551	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$15,090	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$157,706	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$46,056	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$18,767	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$27,184	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$24,772	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				-\$1,292	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				-\$2,567	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SP50AR070604-05				\$6,911	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR01AR073311-04			\$111,556	\$212,681	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR01AR073311-05				\$123,796	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR01AR073908-02				\$0	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR01AR073908-03			\$36,359	\$228,890	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR01AR073908-04				\$198,700	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR079071-01				\$21,408	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR21AR079071-02				\$162,693	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR079774-01				\$117,436	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR21AR079774-02				\$58,543	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR078395-01A1			\$22,557	\$483,770	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	SR01AR078395-02				\$277,318	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3201900722	THE CHILDREN'S HOSPITAL OF PA	3201900722		\$6,099	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3201900722	THE CHILDREN'S HOSPITAL OF PA	3201900722		-\$7	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3021904	DUKE UNIVERSITY	3021904		\$620	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$3,083	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$32,412	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$6,463	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	OS000000041	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	OS000000041		\$13,926	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	OS000000041	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	OS000000041		\$15,790	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$10,172	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$9,225	\$2,276,196	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SR01DK110077-05			\$261,904	\$397,885	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SR01DK115737-04			\$25,749	\$45,479	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SR01DK115737-05				\$196,472	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SR01DK114035-04			\$6,968	\$164,388	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SR03DK118306-02				-\$1,577	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SK08DK122119-03				\$35,752	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK122119-04				\$102,845	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK100866-09			\$571,758	\$728,517	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK100866-10				\$208,527	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK125469-02				\$106,138	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK125469-03				\$259,146	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK122171-02				\$290,901	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK122171-03				\$283,052	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K01DK128379-01				\$44,641	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K01DK128379-02				\$96,860	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K01DK126991-01A1				\$49,941	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K01DK126991-02				\$68,423	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F32DK130521-01				\$58,579	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5F32DK130521-02				\$15,067	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK124549-01A1			\$15,507	\$172,705	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK124549-02				\$186,608	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK128088-01A1			\$74,621	\$270,630	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK128088-02				\$105,644	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R13DK134128-01				\$2,500	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7000000297	BAYLOR COLLEGE OF MEDICINE	7000000297		-\$878	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7000000297	BAYLOR COLLEGE OF MEDICINE	7000000297		\$61,929	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M9121	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M9121		\$4,789	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M9121	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M9121		-\$921	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60069457	THE OHIO STATE UNIVERSITY	60069457		-\$38	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR113109	THE OHIO STATE UNIVERSITY	GR113109		\$37,120	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR118321/SPC-1000004136	THE OHIO STATE UNIVERSITY	GR118321/SPC-1000004136		-\$2	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR118321/SPC-1000004136	THE OHIO STATE UNIVERSITY	GR118321/SPC-1000004136		\$22,532	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60075032	THE OHIO STATE UNIVERSITY	60075032		\$0	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR118321 / SPC-1000004136	THE OHIO STATE UNIVERSITY	GR118321 / SPC-1000004136		\$26,014	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR118321 / SPC-1000004136	THE OHIO STATE UNIVERSITY	GR118321 / SPC-1000004136		\$2,723	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SITE 0263 TRIALNET AFFILIATE	UNIVERSITY OF SOUTH FLORIDA	SITE 0263 TRIALNET AFFILIATE		\$100	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	8451_NCH	INDIANA UNIVERSITY	8451_NCH		-\$720	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S02051-02	THE UNIVERSITY OF IOWA	S02051-02		\$2,174	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S02051-03	THE UNIVERSITY OF IOWA	S02051-03		\$12,005	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	901645-NATIONWIDE	LURIE CHILDREN'S HOSPITAL	901645-NATIONWIDE		\$17,190	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	901645-NATIONWIDE	LURIE CHILDREN'S HOSPITAL	901645-NATIONWIDE		\$7,650	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3200950822-0607	CHILDREN'S HOSPITAL OF PHILADELPHIA	3200950822-0607		\$1,826	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	109938-19114	UNIVERSITY OF ILLINOIS CHAMPAIGN	109938-19114		\$47,104	\$4,129,720	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS085238-05				\$39,948	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS085238-05				\$0	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R33NS101166-03			\$12,510	\$59,917	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS105986-01				-\$43,694	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498



NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1K08NS119878-01A1				\$116,102	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2R01NS085238-06				\$127,690	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	96755C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	96755C		-\$8	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	96755C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	96755C		\$18,370	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NN107 - FX-LEARN	MASSACHUSETTS GENERAL HOSPITAL	NN107 - FX-LEARN		\$26,314	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	104975C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	104975C		\$0	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	104975C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	104975C		\$3,904	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GR124707	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR124707		\$24,313	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	210305-0819-02	THE JACKSON LABORATORY	210305-0819-02		\$468	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	S-001035	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	S-001035		\$35,659	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	S-001035	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	S-001035		\$43,099	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	432107-19D50	VIRGINIA POLYTECHNIC INSTITUTE	432107-19D50		\$4,144	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	432107-19D50	VIRGINIA POLYTECHNIC INSTITUTE	432107-19D50		\$62,391	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	115755C	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	115755C		\$7	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	115755C	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	115755C		\$57	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	10050533-03	THE UNIVERSITY OF UTAH	10050533-03		\$10,547	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	10050533-03	THE UNIVERSITY OF UTAH	10050533-03		\$5,547	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	237416	MASS GENERAL BRIGHAM RESEARCH MANAGEMENT	237416		\$50,640	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	237416	MASS GENERAL BRIGHAM RESEARCH MANAGEMENT	237416		\$44,453	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5(GG015970-02)	COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE	5(GG015970-02)		\$23,631	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5(GG015970-03)	COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE	5(GG015970-03)		\$14,764	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	412670-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412670-19D50		\$1,518	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	412670-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412670-19D50		\$13,063	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	WSU21083 GRANT INDEX 301646	WAYNE STATE UNIVERSITY	WSU21083 GRANT INDEX 301646		\$1,459	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1(GG017672-01)	COLUMBIA UNIVERSITY MEDICAL CENTER	1(GG017672-01)		\$32,413	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1(GG017672-01)	COLUMBIA UNIVERSITY MEDICAL CENTER	1(GG017672-01)		\$2,201	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	MAGANA	HUGO W. MOSER RI AT KENNEDY KRIEGER, INC.	MAGANA		\$61,562	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	MAGANA	HUGO W. MOSER RI AT KENNEDY KRIEGER, INC.	MAGANA		\$64,431	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GR124266 / SPC-1000005767	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR124266 / SPC-1000005767		\$6,026	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GR124266 / SPC-1000005767	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR124266 / SPC-1000005767		\$5,019	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7000001488	BAYLOR COLLEGE OF MEDICINE	7000001488		\$148,006	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7000001488	BAYLOR COLLEGE OF MEDICINE	7000001488		\$6,490	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GR125073	THE OHIO STATE UNIVERSITY	GR125073		\$92,672	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GR128584	THE OHIO STATE UNIVERSITY	GR128584		\$165,476	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	100654089-02-NW	THE UNIVERSITY OF UTAH ARKANSAS CHILDREN'S HOSPITAL	100654089-02-NW		\$10,433	\$1,279,032	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	034146-014	RESEARCH INSTITUTE	034146-014		\$1,009	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A635027	EMORY UNIVERSITY	A635027		\$78,429	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A635027	EMORY UNIVERSITY	A635027		\$7,049	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	OS00000060/317962	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	OS00000060/317962		\$62,047	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1093848-08				\$5,872	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1093848-09				\$360,658	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1126890-05			\$542,072	\$689,397	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131313-05			\$43,200	\$157,295	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1124029-05				\$31,168	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1125489-04				\$40,251	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131386-02 REVISED				\$391	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131386-05			\$372,111	\$491,869	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3U01A1131386-0551				\$686,975	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1134848-04			\$14,976	\$22,806	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1134848-05				\$258,459	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1137567-04				\$34,926	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1137567-05				\$400,585	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1096882-09			\$157,351	\$320,062	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1096882-10				\$220,577	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139511-03			\$11,098	\$11,098	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139511-04				\$243,757	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139511-05				\$129,384	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5F30A1143060-03				\$5,943	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5F30A1143060-04				\$10,039	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3R01A1116917-07A151				\$49,284	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1116917-08			\$170,140	\$383,671	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3R01A1116917-0851				\$14,757	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01A1116917-07A1			\$120,942	\$234,366	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1142885-02				\$50,130	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1140001-02				\$744	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139519-03			\$6,162	\$42,937	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139519-04				\$149,219	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1142433-02				\$28,303	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1143740-02			\$13,388	\$84,228	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1143740-03				\$55,768	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1146581-02			\$5,288	\$313,856	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1149414-02				\$49,665	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1153752-02				\$115,244	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-02				\$251,203	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-02				\$116,751	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-02				\$89,063	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-03				\$179,231	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-03				\$87,269	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-03				\$37,121	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1156328-01				\$118	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1156328-02				\$95,587	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1159735-01				\$60,226	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1159735-02				\$191,791	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01A1151175-01A1			\$146,940	\$334,892	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1151175-02				\$214,556	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1156406-01			\$79,025	\$130,349	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1156406-02				\$129,402	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01A1114581-06			\$17,273	\$219,370	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A114581-07			\$67,678	\$245,368	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1164077-01				\$69,548	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1164077-02				\$147,145	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1U19A1168632-01				\$36,298	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1U19A168632-01				\$53,487	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1U19A168632-01				\$21,310	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A171928-01A1				\$23,932	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AWD7773224-GR205827	GEORGETOWN UNIVERSITY	AWD7773224-GR205827		\$724	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$104,431	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$4,584	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60069338	THE OHIO STATE UNIVERSITY	60069338		-\$1,542	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60069338	THE OHIO STATE UNIVERSITY	60069338		\$5,458	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR113431	THE OHIO STATE UNIVERSITY	GR113431		\$35,763	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0222-11	THE JACKSON LABORATORY	210310-0222-11		\$5,553	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0222-20	THE JACKSON LABORATORY	210310-0222-20		\$22,068	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0223-11	THE JACKSON LABORATORY	210310-0223-11		\$42,285	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1090598-424099	CARNEGIE MELLON UNIVERSITY	1090598-424099		\$58,978	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR115767	THE OHIO STATE UNIVERSITY	GR115767		-\$8	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR115767 / SPC-1000003908	THE OHIO STATE UNIVERSITY	GR115767 / SPC-1000003908		\$814	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR115767 / SPC-1000003908	THE OHIO STATE UNIVERSITY	GR115767 / SPC-1000003908		\$25,767	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR115767 / SPC-1000003908	THE OHIO STATE UNIVERSITY	GR115767 / SPC-1000003908		\$25,975	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	C-SIDE PBMTc 1801	CHILDREN'S HOSPITAL OF LOS ANGELES	C-SIDE PBMTc 1801		\$1,271	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	000522211-SC008	UNIV OF ALABAMA AT BIRMINGHAM	000522211-SC008		-\$3,348	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	310399	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	310399		-\$11	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	310399	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	310399		\$16,606	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR119216	THE OHIO STATE UNIVERSITY	GR119216		\$23,861	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	117625C	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	117625C		\$540	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	117625C	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	117625C		\$8,120	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	248445/A031576	DUKE UNIVERSITY	248445/A031576		\$2,941	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	KEMRI - SALMONELLA TYPHI	KENYA MEDICAL RSRC INSTITUTE	KEMRI - SALMONELLA TYPHI		\$6,170	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	KEMRI - SALMONELLA TYPHI	KENYA MEDICAL RSRC INSTITUTE	KEMRI - SALMONELLA TYPHI		\$21,845	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A538211	EMORY UNIVERSITY	A538211		\$27,487	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A538211	EMORY UNIVERSITY	A538211		\$32,673	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	265416/A034556	DUKE UNIVERSITY	265416/A034556		\$193	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	SUB000000113	UNIVERSITY OF MASS, WORCESTER	SUB000000113		\$67,684	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	SUB000000113	UNIVERSITY OF MASS, WORCESTER	SUB000000113		\$41,039	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	10034797	UNIVERSITY OF CALGARY	10034797		\$13,711	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	10034797	UNIVERSITY OF CALGARY	10034797		\$8,491	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	10034797	UNIVERSITY OF CALGARY	10034797		\$270	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	62690637-192167	STANFORD UNIVERSITY	62690637-192167		\$52,167	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	62690637-192167	STANFORD UNIVERSITY	62690637-192167		\$193,780	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GENFD0002200123	BOSTON CHILDREN'S HOSPITAL	GENFD0002200123		\$10,672	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GENFD0002200123	BOSTON CHILDREN'S HOSPITAL	GENFD0002200123		\$1,178	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GENFD0002272667	BOSTON CHILDREN'S HOSPITAL	GENFD0002272667		\$5,215	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GRT-00002464	THE CHILDREN'S HOSPITAL OF PA	GRT-00002464		\$11,909	\$9,451,549	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-04				\$47,512	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-04				\$17,150	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-04				\$51,729	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K08GM124499-03				-\$92	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K08GM124499-04				\$198,045	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R35GM131875-05				\$342,378	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	7R35GM131875-04				\$165,653	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	430-40-18A	IOWA STATE UNIVERSITY	430-40-18A		\$15,838	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4688187	INDIANA UNIVERSITY	4688187		\$89,314	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GR126469 / SPC-1000006803	THE OHIO STATE UNIVERSITY	GR126469 / SPC-1000006803		\$1,756	\$929,283	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	9116-NCH	INDIANA UNIVERSITY	9116-NCH		\$106,048	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	9116-NCH	INDIANA UNIVERSITY	9116-NCH		\$56,462	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A21-0255-S002	UC DAVIS MEDICAL CENTER	A21-0255-S002		\$47	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD068278-11				\$57,311	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD068278-12				\$190,407	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R25HD086885-05				\$19,362	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD088033-05			\$34,285	\$87,402	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD091347-04			\$275,503	\$315,361	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3R01HD091347-04S1				\$8,203	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD091347-05			\$20,212	\$47,021	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD074594-07				-\$17	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD074594-08				\$366,015	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD098176-02			\$20,211	\$54,018	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD098176-03			\$35,527	\$149,625	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD095976-02				\$1	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD095976-03			\$103,865	\$233,772	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD095976-04				\$188,908	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4R00HD096115-03				-\$31,847	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R00HD096115-04				\$158,151	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R00HD096115-05				\$97,541	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R21HD099575-02			\$5,664	\$97,374	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD100493-02				\$273,979	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD100493-03				\$397,854	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD098175-02			\$356,998	\$536,236	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3R01HD098175-02S1			\$51,163	\$64,663	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD098175-03				\$98,402	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD100420-02			\$76,171	\$401,187	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD100420-03				\$151,541	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R21HD106252-01			\$50,198	\$115,214	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R21HD106252-02			\$19,915	\$67,784	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R11HD107783-01				\$93,660	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R11HD107783-02				\$78,465	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD109000-01			\$8,281	\$153,607	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GR120740	THE OHIO STATE UNIVERSITY	GR120740		\$2,485	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMCS3266	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMCS3266		\$1,166	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	216392	RTI INTERNATIONAL	216392		\$717,686	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3004685877	REGENTS UNIVERSITY OF MICHIGAN	3004685877		\$33,172	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GR101278 / SPC-1000003590	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR101278 / SPC-1000003590		\$17,956	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1644 G VA041	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	1644 G VA041		\$16,374	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R70507-3213	EASTERN MICHIGAN UNIVERSITY	R70507-3213		\$16,370	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R70507-3213	EASTERN MICHIGAN UNIVERSITY	R70507-3213		\$15,639	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OSP2018144	UNIVERSITY OF MASS, WORCESTER	OSP2018144		\$63,130	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OSP2018144	UNIVERSITY OF MASS, WORCESTER	OSP2018144		\$37,068	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	30004942-09	CHILDREN'S NATIONAL MEDICAL CENTER	30004942-09		\$7,554	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	30004942-09	CHILDREN'S NATIONAL MEDICAL CENTER	30004942-09		\$15,621	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	NCH31227-01	LA BIOMEDICAL RESEARCH INST	NCH31227-01		\$12,452	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	FY20.812.008 / 2-5-A9096	UNIVERSITY OF COLORADO DENVER	FY20.812.008 / 2-5-A9096		\$2,559	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	FY20.812.008 / 2-5-A9096	UNIVERSITY OF COLORADO DENVER	FY20.812.008 / 2-5-A9096		\$4,346	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	412575-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412575-19D50		\$21,115	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498

**NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)**

**Fiscal Period 1/1/2022 - 12/31/2022**

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	412575-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412575-19D50		\$38,043	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000004188 / GR119858	THE OHIO STATE UNIVERSITY	SPC-1000004188 / GR119858		\$26,536	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000004188 / GR119858	THE OHIO STATE UNIVERSITY	SPC-1000004188 / GR119858		\$141,999	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A21-0004-S002 - NCH	ANN & ROBERT H. LURIE CHILDREN'S	A21-0004-S002 - NCH		\$47,570	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A21-0004-S002 - NCH	ANN & ROBERT H. LURIE CHILDREN'S	A21-0004-S002 - NCH		\$34,714	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000004338 / GR120536	THE OHIO STATE UNIVERSITY	SPC-1000004338 / GR120536		\$41,605	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD091302	THE MEDICAL COLLEGE OF WI INC.	R01HD091302		\$17,373	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD091302	THE MEDICAL COLLEGE OF WI INC.	R01HD091302		\$7,836	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762		-\$1,220	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762		-\$1,730	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762		\$13,923	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762		\$4,631	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762		\$5,082	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	304848	CHILDREN'S HOSPITAL MEDICAL CENTER	304848		\$41,990	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	304848	CHILDREN'S HOSPITAL MEDICAL CENTER	304848		\$1,665	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OS00000051 / 304848	CHILDREN'S HOSPITAL MEDICAL CENTER	OS00000051 / 304848		\$45,981	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OS00000051 / 304848	CHILDREN'S HOSPITAL MEDICAL CENTER	OS00000051 / 304848		\$4,434	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A574179	EMORY UNIVERSITY	A574179		\$85,612	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A713049	EMORY UNIVERSITY	A713049		\$43,695	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000005458 / GR124885	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000005458 / GR124885		\$33,998	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000005458 / GR124885	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000005458 / GR124885		\$30,467	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$23,587	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$26,041	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$5,622	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$25	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$18,490	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$25,086	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10058860-08-NWCH	THE UNIVERSITY OF UTAH	10058860-08-NWCH		\$3,087	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	000014111-B	CHILDREN'S HOSPITAL OF LOS ANGELES	000014111-B		\$35,216	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	FY22.1167.002	UNIVERSITY OF COLORADO DENVER	FY22.1167.002		\$2,500	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	CON-80003419 (GR114863)	YALE UNIVERSITY	CON-80003419 (GR114863)		\$1,623	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	CON-80003419 (GR114863)	YALE UNIVERSITY	CON-80003419 (GR114863)		\$1,146	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	CON-80003419 (GR114863)	YALE UNIVERSITY	CON-80003419 (GR114863)		\$2,838	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10046978-05-NCH	THE UNIVERSITY OF UTAH	10046978-05-NCH		\$16,930	\$6,444,845	RESEARCH AND DEVELOPMENT	\$82,409,498
AGING RESEARCH	93.866	60067217	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067217		-\$350	\$133,694	RESEARCH AND DEVELOPMENT	\$82,409,498
AGING RESEARCH	93.866	000526371-SC002	BOARD OF TRUSTEES UNIV OF AL	000526371-SC002		\$72,822	\$133,694	RESEARCH AND DEVELOPMENT	\$82,409,498
AGING RESEARCH	93.866	GR122536 / R21AG071133	THE OHIO STATE UNIVERSITY	GR122536 / R21AG071133		\$4,098	\$133,694	RESEARCH AND DEVELOPMENT	\$82,409,498
AGING RESEARCH	93.866	GR122536 / SPC-1000004847	THE OHIO STATE UNIVERSITY	GR122536 / SPC-1000004847		\$8,631	\$133,694	RESEARCH AND DEVELOPMENT	\$82,409,498
AGING RESEARCH	93.866	SPC-10000006285/GR126664	THE OHIO STATE UNIVERSITY	SPC-10000006285/GR126664		\$48,493	\$133,694	RESEARCH AND DEVELOPMENT	\$82,409,498
VISION RESEARCH	93.867	CONTRACT ID 1803	JAEB CENTER FOR HEALTH	CONTRACT ID 1803		\$8,826	\$13,636	RESEARCH AND DEVELOPMENT	\$82,409,498
VISION RESEARCH	93.867	CONTRACT ID 1803	JAEB CENTER FOR HEALTH	CONTRACT ID 1803		\$4,810	\$13,636	RESEARCH AND DEVELOPMENT	\$82,409,498
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0420	OHIO DEPARTMENT OF HEALTH	02560511MH0420		\$0	\$945,774	N/A	\$0
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0723	OHIO DEPARTMENT OF HEALTH	02560511MH0723		\$231,216	\$945,774	N/A	\$0
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0622	OHIO DEPARTMENT OF HEALTH	02560511MH0622	\$33,548	\$714,558	\$945,774	N/A	\$0
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	ASPR	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	ASPR		\$156,806	\$169,832	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	ASPR	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	ASPR		\$20,822	\$169,832	RESEARCH AND DEVELOPMENT	\$82,409,498
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	47318	OHIO DEPARTMENT OF HEALTH	47318		-\$7,796	\$169,832	RESEARCH AND DEVELOPMENT	\$82,409,498
RURAL HEALTH CARE SERVICES OUTREACH, RURAL HEALTH NETWORK DEVELOPMENT AND SMALL HEALTH CARE PROVIDER QUALITY IMPROVEMENT	93.912	HRSA-RCORP-NCH	HOPEWELL HEALTH CENTERS	HRSA-RCORP-NCH		\$47,571	\$47,571	N/A	\$0
GRANTS TO STATES FOR OPERATION OF STATE OFFICES OF RURAL HEALTH	93.913	47582	OHIO DEPARTMENT OF HEALTH	47582		\$5,423	\$5,423	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	0923-2022	COLUMBUS HEALTH DEPARTMENT	0923-2022		\$9,051	\$430,735	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$51,463	\$430,735	RESEARCH AND DEVELOPMENT	\$82,409,498
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$33,708	\$430,735	RESEARCH AND DEVELOPMENT	\$82,409,498
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$6,818	\$430,735	RESEARCH AND DEVELOPMENT	\$82,409,498
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$172,331	\$430,735	RESEARCH AND DEVELOPMENT	\$82,409,498
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$113,430	\$430,735	RESEARCH AND DEVELOPMENT	\$82,409,498
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$43,934	\$430,735	RESEARCH AND DEVELOPMENT	\$82,409,498
HIV CARE FORMULA GRANTS	93.917	02560511QI0322	OHIO DEPARTMENT OF HEALTH	02560511QI0322		\$68,637	\$68,637	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76HA24736-10-00				\$154,039	\$414,207	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	6 H76HA24736-11-01				\$260,168	\$414,207	N/A	\$0
HEALTHY START INITIATIVE	93.926	6 U1VMC46321-01-01				\$1,873	\$1,873	N/A	\$0
ASSISTANCE PROGRAMS FOR CHRONIC DISEASE PREVENTION AND CONTROL	93.945	GRT-00000609 / POW20265546	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000609 / POW20265546		\$7,141	\$7,141	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	OMHAS - 2200518	OHIO DEPARTMENT OF MENTAL HEALTH	OMHAS - 2200518	\$115,000	\$255,186	\$416,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	OMHAS - 2300287	OHIO DEPARTMENT OF MENTAL HEALTH	OMHAS - 2300287		\$21,671	\$416,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	OMHAS - 2200516	OHIO DEPARTMENT OF MENTAL HEALTH	OMHAS - 2200516		\$67,486	\$416,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	OMHAS - 2300286	OHIO DEPARTMENT OF MENTAL HEALTH	OMHAS - 2300286	\$10,000	\$71,940	\$416,283	RESEARCH AND DEVELOPMENT	\$82,409,498
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	2300078	OHIO DEPARTMENT OF MENTAL HEALTH	2300078		\$53,414	\$113,087	N/A	\$0
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	2200026	OHIO DEPARTMENT OF MENTAL HEALTH	2200026	\$54,993	\$59,673	\$113,087	N/A	\$0
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	02560511I00223	OHIO DEPARTMENT OF HEALTH	02560511I00223		\$16,049	\$16,049	RESEARCH AND DEVELOPMENT	\$82,409,498
WORKING CANINE GENETIC MAPPING	93.RD	US001-0000765771	BATTELLE MEMORIAL INSTITUTE	US001-0000765771	\$23,686	\$156,414	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
INFLUENZA VACCINE EFFECTIVENES	93.RD	1758484	BOSTON CHILDREN'S HOSPITAL	1758484		\$1,539	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
MIS-C SUB STUDY	93.RD	75D30120C07725	BOSTON CHILDREN'S HOSPITAL	75D30120C07725		\$2,310	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
LEIDOS CTSMC - TO F1	93.RD	21X121F	LEIDOS BIOMEDICAL RESEARCH, INC	21X121F		\$2,619,727	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
ETCTN NCLN BIOBANK	93.RD	21X228F3	LEIDOS BIOMEDICAL RESEARCH, INC	21X228F3		\$202,772	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
PEDIATRIC NCI-MATCH	93.RD	21X228F4	LEIDOS BIOMEDICAL RESEARCH, INC	21X228F4		\$113,208	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MDNET MATCH SUPPORT	93.RD	21X228F1	LEIDOS BIOMEDICAL RESEARCH, INC	21X228F1		\$454	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BLGSP	93.RD	21X013F	LEIDOS BIOMEDICAL RESEARCH, INC	21X013F		\$103	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
MOUNT SINAI FLU STUDY	93.RD	0258-A504-4609	MOUNT SINAI SCHOOL OF MEDICINE	0258-A504-4609		\$55,889	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
MOUNT SINAI FLU STUDY	93.RD	0258-B504-4609	MOUNT SINAI SCHOOL OF MEDICINE	0258-B504-4609		\$202,390	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
HRSA IDIQ - TO1 (2022)	93.RD	75R60221D00001			\$376,956	\$787,644	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
HRSA IDIQ - TO4 (2022)	93.RD	75R60221D00001/75R60222F3					\$33,418	RESEARCH AND DEVELOPMENT	\$82,409,498
HRSA IDIQ - TO3 (2022)	93.RD	75R60221D00001/75R60222F5					\$59,146	RESEARCH AND DEVELOPMENT	\$82,409,498
NEISS	93.RD	CP5-21131-21-0136				\$181,598	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
NEISS	93.RD	CP5-21131-22-0204				\$240,447	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
HRSA TASK ORDER 8	93.RD	A032743	DUKE UNIVERSITY	A032743		-\$1	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001 P00008				\$4	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001 P00008				\$1	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001 P00010				\$933,883	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001 P00010				\$61,114	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
NCI BCR TO#2 BASE	93.RD	HHSN26100002				\$94,520	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
NCI BCR TO#2 CBA	93.RD	HHSN26100002				\$4,782	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
NCI BCR TO#2 TRAVEL	93.RD	HHSN26100002				\$891	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
NCI BCR TO#2 INT SHIP	93.RD	HHSN26100002				\$7,084	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
MP2PRT LEIDOS TO3	93.RD	21X121FQ3	LEIDOS BIOMEDICAL RESEARCH, INC	21X121FQ3		\$14,804	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
HTMCP NEW CYCLE	93.RD	21X148Q	LEIDOS BIOMEDICAL RESEARCH, INC	21X148Q		\$31,735	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
12XS383 HTMCP DATA COLLECTION	93.RD	12XS383	LEIDOS BIOMEDICAL RESEARCH, INC	12XS383		\$59	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
PEDIATRIC NCI - MATCH APEC1621	93.RD	17X033Q2	LEIDOS BIOMEDICAL RESEARCH, INC	17X033Q2		\$201,697	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
17X033 TO: Q3 BPU ETCTN INCLN	93.RD	17X033	LEIDOS BIOMEDICAL RESEARCH, INC	17X033		\$217,170	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
19X092Q1-LEIDOS-LOH STUDY	93.RD	19X092Q1	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q1		\$18,821	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
MP2PRT-NPC ARAR0331	93.RD	21X121F Q4	LEIDOS BIOMEDICAL RESEARCH, INC	21X121F Q4		\$217	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
MP2PRT - COSGROVE	93.RD	21X121F Q2	LEIDOS BIOMEDICAL RESEARCH, INC	21X121F Q2		\$303,854	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
19X092Q3 - LEIDOS - TEWARI	93.RD	19X092Q3 18X104	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q3 18X104		\$18,748	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BPC EOMI TO7	93.RD	HHSN2612017000151				\$364	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
BPC EOMI TO7	93.RD	HHSN2612017000151				\$30,955	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
CCG-BCR	93.RD	HHSN2612017000151				\$578,349	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
TO6: NUCLEIC ACID EXTRACTIONS	93.RD	HHSN2612017000151				\$46,783	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
CCG BPC DCEG	93.RD	HHSN2612017000151				\$3,348	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
A TARGETED APPROACH TO A SAFER	93.RD	RNG002833-BUDG03 SUB NCH MOD2	KFHPW FORMERLY GROUP HEALTH RI	RNG002833-BUDG03 SUB NCH MOD2		-\$8,300	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
ADENOVIRUS STEM CELL	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621		\$79	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
ADENOVIRUS - OPTION 2	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621		\$268	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
ADENOVIRUS - OPTION 3	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621		\$35,582	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
ORAL VALGANCICLOVIR	93.RD	000509729-001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000509729-001		\$4,244	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
CMV PROFILING IN INFANTS	93.RD	000509729-009	UNIV OF ALABAMA AT BIRMINGHAM	000509729-009		\$3,231	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
OPNA EXPOSURE	93.RD	SPC-1000004616 / GR120172	THE OHIO STATE UNIVERSITY	SPC-1000004616 / GR120172		\$141,270	\$7,402,615	RESEARCH AND DEVELOPMENT	\$82,409,498
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$9,248,015	\$87,569,354			
CORPORATION FOR NATIONAL AND COMMUNITY SERVICE									
AMERICORPS STATE AND NATIONAL	94.006	21AFCOH001	SERVEOHIO	21AFCOH001		\$31,313	\$31,313	N/A	\$0
TOTAL CORPORATION FOR NATIONAL AND COMMUNITY SERVICE						\$31,313			
DEPARTMENT OF HOMELAND SECURITY									

NATIONWIDE CHILDREN'S HOSPITAL INC. AND SUBSIDIARIES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (continued)

Fiscal Period 1/1/2022 - 12/31/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	COVID-19	OHIO DEPARTMENT OF PUBLIC SAFETY	COVID-19		\$658,395	\$658,395	N/A	\$0
TOTAL DEPARTMENT OF HOMELAND SECURITY						\$658,395			
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$9,714,565	\$92,022,232			

**Please Note:**

*Italicized award lines indicate pass-through funding*

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.



# Nationwide Children's Hospital, Inc. and Subsidiaries

## Notes to the Schedule of Expenditures of Federal Awards

December 31, 2022

### **1. Basis of Presentation**

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Nationwide Children's Hospital, Inc. and Subsidiaries under programs of the federal government for the year ended December 31, 2022. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Expenditures reported on the Schedule are reported on the accrual basis of accounting. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

### **2. 10% De Minimis Cost Rate**

Nationwide Children's Hospital, Inc. and Subsidiaries did not use the de minimis cost rate.

# Internal Control and Compliance Reports and Schedule

## Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Senior Management and the Board of Directors  
Nationwide Children's Hospital, Inc. and Subsidiaries

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Nationwide Children's Hospital, Inc. and Subsidiaries (the Corporation), which comprise the consolidated balance sheet as of December 31, 2022, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"), and have issued our report thereon dated April 26, 2023.

### Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

## **Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Corporation's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### **Purpose of This Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Ernst + Young LLP*

April 26, 2023

## Report of Independent Auditors on Compliance for the Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors  
Nationwide Children's Hospital, Inc. and Subsidiaries

### **Report of Independent Auditors on Compliance for the Major Federal Program**

#### ***Opinion on the Major Federal Program***

We have audited Nationwide Children's Hospital, Inc. and Subsidiaries' (the Corporation) compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on the Corporation's major federal program for the year ended December 31, 2022. The Corporation's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Corporation complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended December 31, 2022.

#### ***Basis for Opinion on the Major Federal Program***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Corporation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for the major federal program. Our audit does not provide a legal determination of the Corporation's compliance with the compliance requirements referred to above.

### ***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Corporation's federal programs.

### ***Auditor's Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Corporation's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Corporation's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Corporation's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Corporation's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

### ***Other Matters***

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as follows:

<b>Finding No.</b>	<b>Assistance Listing No.</b>	<b>Program or Cluster Name</b>	<b>Compliance Requirement</b>
2022-001	Various	R&D Cluster	I. Procurement, Suspension and Debarment
2022-002	Various	R&D Cluster	A. Activities Allowed or Unallowed B. Allowable Costs/Cost Principle
2022-003	Various	R&D Cluster	L. Reporting

Our opinion on the major federal program is not modified with respect to these matters.

*Government Auditing Standards* requires the auditor to perform limited procedures on the Corporation's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Corporation's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

### **Report on Internal Control Over Compliance**

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be material weaknesses.

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of

compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. We consider the following deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses.

<b>Finding No.</b>	<b>Assistance Listing No.</b>	<b>Program or Cluster Name</b>	<b>Compliance Requirement</b>
2022-001	Various	R&D Cluster	I. Procurement, Suspension and Debarment
2022-002	Various	R&D Cluster	A. Activities Allowed or Unallowed B. Allowable Costs/Cost Principle
2022-003	Various	R&D Cluster	L. Reporting

A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

*Government Auditing Standards* requires the auditor to perform limited procedures on the Corporation's response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Corporation's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

*Ernst & Young LLP*

September 29, 2023



Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2022

**Section I—Summary of Auditor's Results**

**Financial Statements**

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

           **Yes**   X   **No**

Significant deficiency(ies) identified?

           **Yes**   X   **None Reported**

Noncompliance material to financial statements noted?

           **Yes**   X   **No**

**Federal Awards**

Internal control over major federal program:

Material weakness(es) identified?

  X   **Yes**            **No**

Significant deficiency(ies) identified?

           **Yes**   X   **None Reported**

Type of auditor's report issued on compliance for major federal program:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

  X   **Yes**            **No**

Identification of major federal program:

**Assistance Listing Numbers**

**Name of Federal Program or Cluster**

Various

R&D Cluster

Dollar threshold used to distinguish between Type A and Type B programs:

\$ 2,760,666

Auditee qualified as low-risk auditee?

           **Yes**   X   **No**

Nationwide Children's Hospital, Inc. and Subsidiaries  
Schedule of Findings and Questioned Costs (continued)

**Section II—Financial Statement Findings**

No matters were reported.

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs**

**Finding 2022 – 001**

*Identification of the federal program:*

**Federal Agency:** Department of Health and Human Services

**Assistance Listing No., Award Name, Award Number and Pass-Through Agency:**

<b>Assistance Listing</b>	<b>Award Name</b>	<b>Award Number</b>	<b>Pass-Through Agency</b>
93.127	Emergency Medical Services For Children	5 U03MC28844-07-00	
93.136	Injury Prevention And Control Research And State And Community Based Programs	5 R49CE003074-03-00	
93.136	Injury Prevention And Control Research And State And Community Based Programs	1 R01CE003349-01-00	
93.136	Injury Prevention And Control Research And State And Community Based Programs	5 R49CE003074-03-00	
93.137	Community Programs To Improve Minority Health Grant Program	5 CPIMP201202-02-00	
93.242	Mental Health Research Grants	5R01MH117594-04	
93.297	Teenage Pregnancy Prevention Program	5 TP1AH000212-02-00	
93.297	Teenage Pregnancy Prevention Program	5 TP1AH000212-03-00	
93.353	21ST Century Cures Act – Beau Biden Cancer Moonshot	1U54CA231641-01	
93.353	21ST Century Cures Act – Beau Biden Cancer Moonshot	1U01CA232488-01	
93.378	Integrated Care For Kids Model	2B2CMS331798-03-00	Centers for Medicare & Medicaid Services
93.590	Community-Based Child Abuse Prevention Grants	G-2223-22-0246	Ohio Children's Trust Fund
93.837	Cardiovascular Disease Research	5R01HL135103-05	
93.837	Cardiovascular Disease Research	5R01HL157491-02	
93.838	Lung Disease Research	1R01HL157039-01	
93.838	Lung Disease Research	5R01HL157039-02	
93.839	Blood Disease And Resources Research	1R01HL157208-01A1	
93.846	Arthritis, Musculoskeletal And Skin Disease Research	5R01AR073908-03	

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs**

Assistance Listing	Award Name	Award Number	Pass-Through Agency
93.846	Arthritis, Musculoskeletal And Skin Disease Research	1R01AR078395-01A1	
93.846	Arthritis, Musculoskeletal And Skin Disease Research	5R01AR073311-04	
93.847	Diabetes, Digestive, And Kidney Disease Extramural Research	1R01DK128088-01A1	
93.847	Diabetes, Digestive, And Kidney Disease Extramural Research	5U01DK100866-09	
93.855	Allergy And Infectious Disease Research	1R01AI151175-01A1	
93.855	Allergy And Infectious Disease Research	5R01AI126890-05	
93.855	Allergy And Infectious Disease Research	5R01AI096882-09	
93.855	Allergy And Infectious Disease Research	5R01AI146581-02	
93.855	Allergy And Infectious Disease Research	5R01AI096882-09	
93.855	Allergy And Infectious Disease Research	5R01AI116917-08	
93.855	Allergy And Infectious Disease Research	5R01AI114581-07	
93.865	Child Health And Human Development Extramural Research	5R01HD095976-03	
93.865	Child Health And Human Development Extramural Research	5R01HD091347-04	
93.865	Child Health And Human Development Extramural Research	5R01HD098175-02	
93.865	Child Health And Human Development Extramural Research	5R01HD100420-02	
93.870	Maternal, Infant And Early Childhood Home Visiting Grant	02560511MH0622	
93.870	Maternal, Infant And Early Childhood Home Visiting Grant	02560511MH0622	Ohio Department of Health

*Criteria or specific requirement (including statutory, regulatory or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

## Nationwide Children’s Hospital, Inc. and Subsidiaries

### Schedule of Findings and Questioned Costs (continued)

#### **Section III—Federal Award Findings and Questioned Costs**

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in ‘Standards for Internal Control in the Federal Government’ issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

#### *Section 200.214 Suspension and Debarment*

“Non-Federal entities are subject to the non-procurement debarment and suspension regulations implementing Executive Orders 12549 and 12689, 2 CFR part 180. The regulations in 2 CFR part 180 restrict awards, subawards, and contracts with certain parties that are debarred, suspended, or otherwise excluded from or ineligible for participation in Federal assistance programs or activities.”

#### *Condition:*

Nationwide Children’s Hospital (the Corporation) uses a third-party to perform its suspension and debarment checks on a monthly basis. However, we noted the following matters:

- The Corporation did not retain the monthly supporting documentation related to the monthly suspension and debarment check. The suspension and debarment checks performed at year-end were retained.
- The Corporation does not have a process to reconcile the vendor list provided to the third-party vendor with the results received from the third-party vendor after the suspension and debarment checks are performed to ensure the listing is complete.
- The third-party vendor does not have a SOC 1 (System and Organization Controls) Report. The Corporation relied on the results of the suspension and debarment checks performed by the third-party vendor without implementing an internal process to ensure the results provided by the third-party vendor were accurate.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Schedule of Findings and Questioned Costs (continued)

#### **Section III—Federal Award Findings and Questioned Costs (continued)**

In addition, the Corporation performs a suspension and debarment check of all new vendors prior to activating them in the procurement system. The Corporation did not consistently maintain supporting documentation to support the vendor was checked for suspension and debarment before the-“new”-vendor was set up in the procurement system.

##### *Cause:*

The Corporation does not have internal controls in place to require supporting documentation be maintained over the monthly suspension and debarment checks including documentation of management's review and approval.

The Corporation does not have internal controls in place to review the accuracy of third-party reports and to require a reconciliation between the vendor list sent to the third-party vendor and the results provided by the third-party vendor.

The Corporation does not have internal controls in place to require supporting documentation be maintained over the suspension and debarment check performed on new vendors.

##### *Effect or potential effect:*

The Corporation's vendors may not be screened for suspension and debarment, or the suspension and debarment results may not be accurate.

A vendor may be set up in the procurement system that is suspended or debarred.

##### *Questioned costs:*

None

##### *Context:*

We tested a sample of 40 new vendors set up in the procurement system in 2022 and noted four instances where management did not retain the supporting documents of its review of suspension and debarment for the new vendor set up.

## Nationwide Children's Hospital, Inc. and Subsidiaries

### Schedule of Findings and Questioned Costs (continued)

#### **Section III—Federal Award Findings and Questioned Costs (continued)**

The federal portion of procurement expenditures subject to suspension and debarment was approximately \$8,600,000 which represents approximately 10.5% of the R&D Cluster federal expenditures.

The total amount reported on the schedule of expenditures of federal awards (Schedule) for the R&D cluster is \$82,409,498.

*Identification as a repeat finding, if applicable:*

Not a repeat finding

*Recommendation:*

The Corporation should implement the following internal controls:

- The monthly suspension and debarment review process
- Reconciliation of the number of vendor files sent to the third-party vendor with the number of files received from the third-party vendor with the suspension and debarment results and review of the accuracy of the suspension and debarment results performed by the third-party vendor
- Maintenance of the supporting documentation over the suspension and debarment checks performed on new vendors

*Views of responsible officials:*

Management agrees with the recommendation.

Management's corrective action plan includes:

- Review suspension and debarment – Management will review the monthly third-party vendor screening results. Management will retain documentation of the review and supporting documents used in the review.
- Reconciliation – Management will implement a process to reconcile the number of vendor files sent to the third-party screening vendor with the number screened. Management will memorialize this reconciliation.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs (continued)**

- Accuracy – Management will implement a process to verify the accuracy of the results produced by the third-party vendor. Management will memorialize this review.
- Initial screening – Management will implement a process to ensure that supporting documentation of the initial screening process is maintained.

**Finding 2022 – 002**

*Identification of the federal program:*

**Federal Agency:** Department of Health and Human Services

**Assistance Listing No., Award Name and Award Number:**

- 93.297 Teenage Pregnancy Prevention Program – Award No: 5 TP1AH000212-02-00
- 93.855 Allergy And Infectious Diseases Research – Award No: 5R01AI126890-05, 5U01AI131386-05; and 5R01AI146581-02

**Pass-Through Grantor:** None

**Pass-Through Award Number:** None

**Pass-Through Award Period:** Various

*Criteria or specific requirement (including statutory, regulatory, or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal



## Nationwide Children's Hospital, Inc. and Subsidiaries

### Schedule of Findings and Questioned Costs (continued)

#### **Section III—Federal Award Findings and Questioned Costs (continued)**

award. These internal controls should be in compliance with guidance in 'Standards for Internal Control in the Federal Government' issued by the Comptroller General of the United States or the 'Internal Control Integrated Framework,' issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

45 CFR Part 75 Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards, Appendix IX to Part 75—Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts with Hospitals, states:

"Charges for salaries and wages of individuals other than members of the professional staff will be supported by daily time and attendance and payroll distribution records. For members of the professional staff, current and reasonable estimates of the percentage distribution of their total effort may be used as support in the absence of actual time records."

"In order to qualify as current and reasonable, estimates must be made no later than one month (though not necessarily a calendar month) after the month in which the services were performed. Estimates determined before the performance of services, such as budget estimates on a monthly, quarterly, or yearly basis do not qualify as estimates of effort spent."

#### *Condition:*

The Corporation did not obtain effort certifications consistently for all employees' salaries and wages for the year ended December 31, 2022.

Effort certifications were not timely reviewed and approved consistently for all employees' salaries and wages for the year ended December 31, 2022.

#### *Cause:*

The Corporation has internal controls in place to require effort certifications be retained for all employees who charge effort to the R&D Cluster, however, they are not suitably designed to ensure certifications are obtained for all employees and on a timely basis.

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs (continued)**

*Effect or potential effect:*

The Corporation charged salary expense for employees who did not certify their time; therefore, the salaries charged to the program could not be supported.

Effort certifications were not timely received; therefore, the effort certified may not be accurate.

*Questioned costs:*

\$17,639 which includes the salaries and wages charged to the grant plus the related fringe and indirect expenses.

*Award Information:*

Assistance Listing 93.297 Teenage Pregnancy Prevention Program:

Award No: 5 TP1AH000212-02-00 – \$2,555

Assistance Listing 93.855 Allergy And Infectious Diseases Research:

Award No.:

5R01AI126890-05 – \$828

5U01AI131386-05 – \$10,963

5R01AI146581-02 – \$3,293

*Context:*

We tested a sample of 40 salaries and wages (\$161,265) and noted 4 instances (\$17,639) where management did not obtain effort reports to support the salaries and wages charged to the R&D Cluster.

In addition, we noted five instances (\$4,262) where the effort report was not signed timely.

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs (continued)**

Total salaries and wages charged to the R&D Cluster were \$31,468,443 for the year ended December 31, 2022.

The total amount reported on the Schedule for the R&D Cluster is \$82,409,498.

*Identification as a repeat finding, if applicable:*

Not a repeat finding

*Recommendation:*

The Corporation should review its effort certification policies and procedures and implement more robust internal controls to ensure effort certifications are received and received timely for all employees charging effort to the R&D Cluster.

*Views of responsible officials:*

Management agrees with the recommendation. Management will implement the following changes to Time and Effort practices.

- Review and revise Time and Effort internal policy to include more robust internal controls.
- Develop escalation procedures for delayed certification.
- Outstanding time and efforts to be certified.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs (continued)**

**Finding 2022 – 003**

*Identification of the federal program:*

**Federal Agency:** Department of Health and Human Services

**Assistance Listing No, Award Name, Award Number and Pass-through Entity:**

**These federal awards were added to the R&D Cluster:**

Assistance Listing	Award Name	Award Number	Pass-Through Entity
93.127	Emergency Medical Services For Children	EIIC	University Hospitals Cleveland Medical Center
93.226	Research On Healthcare Costs, Quality and Outcomes	1R01HS029183-01	
93.361	Nursing Research	FY22.1180.001	University of Colorado Denver
93.575	Child Care and Development Block Grant	Ohio Children’s Alliance	Ohio Children’s Alliance
93.596	Child Care Mandatory And Matching Funds of the Child Care and Development Fund	COVID-19	Ohio Child Care Resource and Referral Association
93.838	Lung Diseases Research	10059528-01-NWC	The University of Utah
93.846	Arthritis, Musculoskeletal and Skin Diseases Research	GRANT ID: GRT-00001510	Children’s Hospital of Philadelphia
93.855	Allergy and Infectious Diseases Research	034146-014	Arkansas Children’s Hospital Research Institute
93.855	Allergy and Infectious Diseases Research	A635027	Emory University
93.855	Allergy and Infectious Diseases Research	OS00000060/317962	Cincinnati Children’s Hospital Medical Center
93.865	Child Health and Human Development Extramural Research	9116-NCH	Indiana University
93.865	Child Health and Human Development Extramural Research	A21-0255-S002	UC Davis Medical Center
93.867	Vision Research	CONTRACT ID 1803	JAEB Center For Health

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs (continued)**

**These federal awards were removed from the R&D Cluster:**

<b>Assistance Listing</b>	<b>Award Name</b>	<b>Award Number</b>	<b>Pass-Through Entity</b>
16.575	Crime Victim Assistance	2022-SVAA-134716708	Crime Victims Assistance
16.575	Crime Victim Assistance	2022-VOCA-134716701	Crime Victims Assistance
16.575	Crime Victim Assistance	2022DVF42	Crime Victims Assistance
16.575	Crime Victim Assistance	2023-VOCA-135104760	Crime Victims Assistance
21.019	Coronavirus Relief Fund	2020-CARES-78	Crime Victims Assistance
93.110	Maternal and Child Health Federal Consolidated Programs	1 R40MC37541-01-00	
93.110	Maternal and Child Health Federal Consolidated Programs	RPPN	University Hospitals Cleveland Medical Center
93.110	Maternal and Child Health Federal Consolidated Programs	GR124424/SPC-1000005299	The Ohio State University
93.110	Maternal and Child Health Federal Consolidated Programs	GR127800 SPC-1000006745	The Ohio State University
93.110	Maternal and Child Health Federal Consolidated Programs	MCHB 436 22-23	Hemophilia Foundation of Michigan
93.558	Temporary Assistance for Needy Families	25-21-3536	Franklin County Department of Job And Family Services
93.575	Child Care and Development Block Grant	IECMH	Ohio Children's Alliance
93.590	Community-Based Child Abuse Prevention Grants	G-2223-22-0246	Ohio Childrens Trust Fund
93.590	Community-Based Child Abuse Prevention Grants	G-2223-22-0246-1	Ohio Childrens Trust Fund
93.632	University Centers for Excellence in Developmental Disabilities Education, Research, and Service	GR125049	The Ohio State University
93.632	University Centers for Excellence in Developmental Disabilities Education, Research, and Service	GR128419	The Ohio State University
93.778	Medical Assistance Program	GR124661	The Ohio State University
93.870	Maternal, Infant and Early Childhood Home Visiting Grant	02560511MH0622	Ohio Department of Health
93.959	Block Grants for Prevention and Treatment of Substance Abuse	2200026	Ohio Department of Mental Health

## Nationwide Children’s Hospital, Inc. and Subsidiaries

### Schedule of Findings and Questioned Costs (continued)

#### **Section III—Federal Award Findings and Questioned Costs (continued)**

*Criteria or specific requirement (including statutory, regulatory, or other citation):*

Section 200.303 of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in ‘Standards for Internal Control in the Federal Government’ issued by the Comptroller General of the United States or the ‘Internal Control Integrated Framework,’ issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

2 CFR 200.510 requires that the “auditee must also prepare a Schedule of Expenditures of Federal Awards for the period covered by the auditee’s financial statements which must include the total Federal awards expended in accordance with Section 200.502.” These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States and the “Internal Control Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

*Condition:*

The Schedule of Expenditures of Federal Awards prepared by the Corporation did not appropriately reflect the federal expenses related to the R&D Cluster. The final Schedule was corrected for the differences identified.

*Cause:*

The Corporation did not design internal controls over the review and approval of the Schedule to ensure the appropriate federal awards were included in the R&D Cluster.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

**Section III—Federal Award Findings and Questioned Costs (continued)**

*Effect or potential effect:*

Federal awards were inappropriately included and excluded from the R&D Cluster.

*Questioned costs:*

None

*Context:*

Total R&D Cluster expenses included on the draft Schedule were \$84,223,943 for the year ended December 31, 2022. Total R&D expenses included on the final Schedule were \$82,409,498 for the year ended December 31, 2022. Total expenditures on the Schedule did not change. See the federal programs added and removed from the R&D Cluster in the *Information on Federal Programs* section above.

*Identification as a repeat finding, if applicable:*

Not a repeat finding

*Recommendation:*

We recommend that management implement more robust management review internal controls to ensure accurate reporting of federal awards on the Schedule.

*Views of responsible officials:*

Management agrees with the recommendation. Management will implement the following changes to the management of the Schedule of Expenditures.

- Review and validation that grants are listed under the correct cluster.

## **EY | Building a better working world**

**EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.**

**Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.**

**Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.**

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via [ey.com/privacy](https://ey.com/privacy). EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit [ey.com](https://ey.com).

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2023 Ernst & Young LLP.  
All Rights Reserved.

**[ey.com](https://ey.com)**





**Management's Corrective Action Plan  
For the Year Ended December 31, 2022**

**Finding 2022-001**

<b>Grantor:</b>	Department of Health and Human Services
<b>Federal Program:</b>	Various
<b>Assistance Listing #:</b>	Various
<b>Pass-through Grantor</b>	None
<b>Pass-Through Award Number</b>	None
<b>Pass-through Award Period</b>	None
<b>Award Year:</b>	Fiscal year 2022 1/1/2022 – 12/31/2022
<b>Award Number:</b>	None

Management agrees with the recommendation. Management will implement the following changes to its suspension and debarment practices.

**Corrective Action Plan and Anticipate Completion Date**

Management agrees with the recommendation.

- Review suspension and debarment– Management will review the monthly third-party vendor screening results. Management will retain documentation of the review and supporting documents used in the review.
- Reconciliation – Management will implement a process to reconcile the number of vendor files sent to the third-party screening vendor with the number screened. Management will memorialize this reconciliation.
- Accuracy – Management will implement a process to verify the accuracy of the results produced by the third-party vendor. Management will memorialize this review.

Responsible Person: Kathleen Dunn, JD – VP and Chief Compliance Officer

Effective Date: October 1, 2023



Management's corrective action plan includes:

- Initial screening – Management will implement a process to ensure that supporting documentation of the initial screening process is maintained.

Responsible Person: Mary Beth Colatruglio, CPA – Director of Accounting

Effective Date: October 1, 2023

### **Finding 2022-002**

<b>Grantor:</b>	Department of Health and Human Services
<b>Federal Program:</b>	Teenage Pregnancy Prevention Program Allergy And Infectious Diseases Research
<b>Assistance Listing #:</b>	93.267 93.855
<b>Pass-through Grantor</b>	None
<b>Pass-Through Award Number</b>	None
<b>Pass-through Award Period</b>	Various
<b>Award Year:</b>	Fiscal year 2022 1/1/2022 – 12/31/2022
<b>Award Number:</b>	5 TP1AH000212-02 5R01AI126890-05 5U01AI131386-05 5R01AI146581-02

Management agrees with the recommendation. Management will implement the following changes to Time and Effort practices.

### **Corrective Action Plan and Anticipated Completion Date**

Management's corrective action plan includes:

- Review and revise Time and Effort internal policy to include more robust internal controls.
- Develop escalation procedures for delayed certification.
- Outstanding time and efforts to be certified.

Responsible person: Aaron Ufferman, Director, Sponsored Projects

Completion Date: December 31, 2023.



### **Finding 2022-003**

<b>Grantor:</b>	Department of Agriculture and Department of Health and Human Services
<b>Federal Program:</b>	Various
<b>Assistance Listing #:</b>	Various
<b>Title:</b>	Schedule of Expenditures of Federal Awards
<b>Award Year:</b>	Fiscal year 2021 1/1/2022 – 12/31/2022
<b>Award Number:</b>	Various

Management agrees with the recommendation. Management will implement the following changes to the management of the Schedule of Expenditures.

### **Corrective Action Plan and Anticipate Completion Date**

Management's corrective action plan includes:

- Review and validation that grants are listed under the correct cluster.

Responsible Person: Aaron Ufferman, Director, Sponsored Projects, Natasha Collins, Director of Research Accounting

Completion Date: December 31, 2023



# NATIONWIDE CHILDREN'S

*When your child needs a hospital, everything matters.<sup>SM</sup>*

**Nationwide Children's Hospital**

**Schedule of Prior Year Federal Award  
Findings and Questioned Costs**

**For the Year Ended December 31, 2022**

**Finding 2021-001 COVID-19 Provider Relief Fund**

**Summary of finding:**

Management did not retain documentation over the review and approval of the PRF terms and conditions reporting (T&Cs).

Management did not retain documentation over its review and approval of the lost revenue calculation and the report submitted in the HHS HRSA portal.

Management did not retain supporting documentation over certain payroll expenses.

Total expenses reported in the HHS HRSA portal for period 1 and period 2 did not agree to the books and records of Nationwide.

Status of finding: Fully corrected

Comments: Management submitted a Corrective Action to HRSA in which HRSA concluded that NCH satisfactorily resolved the finding. The Corrective Action included the following:

- Documentation of CFO review of PRF terms, conditions, and associated HHS filing.
- Validation of completeness of expenses.
- Correction of reporting error in reporting period 5 related to funds received in 2022.